Release – Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System

Research News and Market Data on NTRB

Preapproval regulatory submissions for the proposed global brand name are being prepared for the US FDA, EU EMA, and international agencies

ORLANDO, Fla., Nov. 17, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB), a pharmaceutical company developing proprietary transdermal drug delivery systems, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), dated November 3, 2026, for commercial brand name trademarks for its lead product, an abuse-deterrent fentanyl transdermal system. Nutriband intends to secure full trademark registration and intellectual property rights for its commercial brand names in the United States and internationally.

In developing the commercial brand name, extensive naming research was conducted to ensure physicians, pharmacists, and patients can clearly distinguish the proprietary name from existing medications with similar spellings, appearances, or pronunciations (look-alike/sound-alike names). Selecting a distinct, non-misleading brand name is a critical patient-safety measure designed to prevent dispensing errors and potential serious adverse medical outcomes.

The company is currently preparing to submit its proposed global brand name to the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other international regulatory bodies through dedicated preapproval pathways. These pathways allow regulators to review and approve a pharmaceutical brand name ahead of formal New Drug Application (NDA) or Marketing Authorization Application (MAA) filings.

Formulated with proprietary AVERSA™ technology, Nutriband’s lead product has the potential to become the world’s first transdermal fentanyl patch engineered to deter intentional abuse and misuse while reducing the risk of accidental exposure.

Nutriband’s abuse-deterrent fentanyl transdermal system has the potential to reach peak annual U.S. sales of between $80 million and $200 million.1 While initially concentrating on the U.S. market, the unmet medical need for adequate pain management is a global problem, and ongoing development is targeted at major medical markets worldwide.

Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

1 Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who depend on them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband, Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ”believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc.

Release – NanoViricides, Inc. Has Filed its Quarterly Report – Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials – One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)

Research News and Market Data on NNVC

Tuesday, 17 November 2026 08:45 AM

SHELTON, CT / ACCESS Newswire / November 17, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2026 with the Securities and Exchange Commission (SEC) on Monday, November 16, 2026. The report can be accessed at the SEC website ( https://www.sec.gov/Archives/edgar/data/1379006/000110465926128532/nnvc-20260930x10q.htm).

In the reported quarter, we have made significant achievements and have successfully taken NV-387 in two separate Phase II clinical trials for evaluating its antiviral effectiveness as a broad-spectrum antiviral agent.

Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Phase II Clinical Trials, towards the end of the reported quarter

  • A Phase II Clinical Trial to evaluate NV-387 Oral Gummies as a Treatment for Ebola Bundibugyo Virus (BDBV) Disease began enrollment on September 23, 2026.
    • There is no drug nor vaccine licensed for the novel Ebola BDBV strain.
    • WHO has declared a Public Health Emergency of International Concern (PHEIC) for Ebola on May 15, 2026.
    • Ebola has caused 11,407 confirmed cases and 5,572 total confirmed deaths across several nations, as of November 14, 2026. In the Democratic Republic of the Congo (DRC) alone, there were 11,376 confirmed cases and 5,568 confirmed deaths i.
    • WHO began a clinical trial called “PARTNERS” to evaluate (i) infusion of a monoclonal antibody cocktail MBP134, (ii) infusion of remdesivir, and (iii) infusion of both of these drugs, comparing the treatments against a control group, in July, 2026. There is no publicly available data from this clinical trial as of now.
    • WHO also began a clinical trial called “Tumaini” to evaluate certain vaccines for BDBV, at the end of October, 2026.
    • NV-387 Oral Gummies is the Only Oral Drug currently in clinical trial for Ebola to the best of our knowledge. NanoViricides has funded this clinical trial solely on its own to date.
  • A Phase II Clinical Trial to evaluate NV-387 Oral Gummies as a Treatment for Mpox (Monkeypox) Virus (MPXV) Disease has started with the opening of a clinical trial site on September 23, 2026.
    • There is no drug licensed for the Mpox Clade Ia/Ib strains nor for the Mpox Clade IIa/IIb strains at present. Clade I viruses produce significantly greater morbidity and mortality, and more contagious, than the Clade II Mpox viruses.
    • Clinical trials of the drug tecovirimat for the treatment of Mpox Clade I as well as for Clade II have failed to demonstrate effectiveness.
    • A clinical trial of another drug brincidofovir has started in January, 2025. As of December 2025, it had enrolled 50 subjects, and the drug was found to show no new safety signals (i.e. drug-related toxicities), according to a press release ii. Brincidofovir carries a black box warning; has known issues with gastroenteric toxicity and hepatotoxicity, and requires physician supervision, according to its prescribing information iii.
    • Mpox Clade II, has become endemic in the Western World, including the USA, where it is primarily transmitted in Men-having-sex-with-men population.
    • Mpox Clade I community spread may be occurring in small outbreaks in the USA, according to the CDC iv.
    • A vaccine Jynneos, is FDA-approved for Smallpox and MPox. However, the effectiveness of 2-dose JYNNEOS vaccine against disease progression (not infection prevention) after 2-doses is only 66.6% in HIV negative subjects and 44.8% in HIV positive subjects, for MPox Clade II, based on US surveillance data v. It is suggested that its efficacy against the more severe Clade I is likely even less.

During the reported quarter, we engaged in completing the development of remote site in DR Congo to prepare it for conducting a clinical trial of NV-387 Oral Gummies for Mpox.

Additionally, as of the end of May 2026, we began preparing the documentation for obtaining regulatory approval to conduct a clinical trial of NV-387 Oral Gummies for the treatment of Ebola BDBV. We received an approval to conduct this clinical trial as of the first week of August, 2026 from ACOREP, the regulatory agency in DRC. Since then we have been engaged in setting up Ebola Treatment Centers for this clinical trial, and a clinical pathology lab with quantitative reverse transcriptase PCR (q-RT-PCR) instrumentation and analysis capability on site. This q-RT-PCR capability in particular has helped us with rapid diagnostics and decision-making in the clinical trial.

Measles Drug Program – NV-387 Oral Formulations

  • An Orphan Drug Designation (ODD) was granted for NV-387 for the treatment of Measles by the US FDA on or about April 27, 2026.
  • A “Rare Pediatric Disease Drug” (RPDD) designation was granted for NV-387 for the treatment of Measles by the US FDA in May, 2026.
  • The RRPD will enable us to obtain a Priority Review Voucher (PRV) upon drug approval from the FDA, which is a tradable instrument. Recently PRVs have fetched as much as $200 million in sales vi.
  • We intend to engage into a Phase II Clinical Trial of NV-387 as a Treatment for Measles next.
  • There is a raging epidemic of Measles in Bangladesh since March, 2026, that has caused 249,569 suspected cases and 1,348 deaths as of November 17, 2026 vii.
  • There have been 5,412 confirmed Measles cases in the United States in 2026, as of As of November 12, 2026, with at least 6 confirmed deaths.
  • USA has lost the Measles elimination status achieved in year 2000 due to sustained outbreaks.
  • Measles is endemic in most parts of the world.
  • Although there is an effective vaccine for Measles, the disease is highly contagious, and the virus becomes airborne leading to multiple infections per patient. Vaccine hesitancy as well as reduced vaccine response due to chronic ailments contribute to the outbreak cases.
  • Vaccines cannot treat a patient with clinical signs. Additionally, post-exposure vaccination has limited effectiveness because for the vaccine to become effective requires at least 2-3 weeks.
  • There is no licensed drug to treat a patient with Measles. This is an unmet medical medical need.
  • We plan on advancing NV-387 for the treatment and prophylaxis of Measles in the USA. We intend to obtain non-dilutive funding such as US government grants for this development.

NV-387 Pediatric Usage

We have recently completed a juvenile mouse pups toxicology study with repeated dosing in 4-day old pups. Under the conditions of this study, the No Observed Adverse Effect Level (NOAEL) was determined to be 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing period. This was actually the highest dose level tested. Therefore, a Maximum Tolerable Dose (MTD) could not be estimated viii.

This study suggests that NV-387 dosing would be reasonably safe in infants as young as 1 year old. Measles and RSV are primarily pediatric diseases. Mpox Clade I as well as Ebola BDBV in DRC have disproportionately affected children. Thus the potential of NV-387 as an oral pediatric drug would be significant if further established in clinical studies. Company Financials

We reported that, as of September 30, 2026, we had cash and cash equivalent current assets balance of approximately $2.98 Million. In addition, we reported approximately $9.56 Million in total Assets including $6.28 Million of Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $3.1 Million.

The net cash utilized during the three months ended September 30, 2026 was approximately $3.64 Million. This included certain non-recurring expenditures including R&D expenditures for the Phase II clinical trials.

Based on budgeting considerations, we reported that we do not have sufficient funding in hand to continue operations through November 16, 2027, for our planned objectives that include:

  1. Completing the Phase II clinical trial of NV-387 for MPox infection in Central Africa
  2. Completing the Phase II clinical trial of NV-387 for Ebola infection in Central Africa
  3. If successful, initiating appropriate Phase III clinical trials towards licensure
  4. Initiating a Phase II clinical trial of NV-387 as a Treatment for Measles
  5. Initiating Phase II clinical trials of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI)
  6. Bringing the above clinical trials under US FDA IND applications
  7. Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA.

As such, we will continue to adjust our business plan to match available funding.

We are seeking non-dilutive funding for which many of our above activities may be eligible.

We continue to have access to an “At-The-Market” common stock facility under a shelf registration, with D. Boral Capital, LLC, the sales agent. We also note that an additional gross cash financing of $6.25 Million would result into the Company if and when the Series A warrants from the November, 2025 financing are exercised.

Additionally, we continue to have access to an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. No funds have been drawn on this facility as of now.

At present, we have sufficient funding to execute and complete the Phase II clinical trial of NV-387 for Mpox infection and the Phase II clinical trial of NV-387 for Ebola in DRC according to our plans and projections.

We believe our regulatory developments for the orphan diseases and for bioterrorism agents response, provide for a rapid regulatory pathway for US FDA licensure of NV-387, with potential for non-dilutive grant and contracts funding, as well as possible direct US Government acquisition contracts, if NV-387 is approved for one of the agents that the US Government stockpiles drugs for. We believe that these early stage revenue opportunities would help us fuel the commercial drug development of NV-387 towards the large markets in RSV, Influenza, and other viral infections; as well as to further advance our NV-HHV-1 pan-herpesvirus drug candidate, among others.

We believe that the MPox clinical trial, if successful would help us advance NV-387 towards regulatory approval for Smallpox in the USA. Smallpox is considered an important bioterrorism agent. Two drugs have been stockpiled in the US Strategic National Stockpile for Smallpox preparedness, namely TPOXX and TEMBEXA, at the cost of billions of dollars. However, the virus can readily escape TPOXX by a single point mutation. TEMBEXA requires physician care during treatment, making it unsuitable as a bioterrorism response agent. Thus there is a need for a better antiviral agent.

We believe that the Ebola clinical trial, if successful would help us advance NV-387 towards regulatory approval for Ebola and Marburg in the USA. Ebola preparedness is a priority for the US Government. To this end, the US Agency BARDA has recently signed a contract worth $270 million for re-supply of Infamez (Regeneron), an antibody cocktail that requires infusions ix. Infamez is licensed for Ebola Zaire virus, but was not included in the clinical trial list in the WHO PARTNERS clinical trial for Ebola BDBV.

A drug that can treat Ebola BDBV, and more broadly, any Ebola virus type, would be of great value to the US Government’s preparedness portfolio, we believe. If NV-387 demonstrates efficacy in our Phase II clinical trial against Ebola BDBV, we believe that it will be of great interest, as a broad-spectrum antiviral drug, that is orally available.

Viruses are Unlikely to Escape NV-387, because of how the drug is designed

No matter how much a virus changes, the virus continues to bind to the sulfated proteoglycan attachment receptor(s) of the host which the virus needs to cause infection as well as for human-to-human transmission. NV-387 is designed to mimic the critical features of the conserved attachment receptors on the host-side that over 90% of viruses are known to use. Thus, NV-387 is designed such that viruses are unlikely to escape it even as they mutate.

This escape-resistant drug feature of NV-387 is designed to solve the biggest problem in antiviral medical countermeasures: Viruses readily evolve to escape the countermeasures in the field, whether vaccines, antibodies, or traditional small chemical drugs.

NV-387 is a Novel Broad-Spectrum Antiviral Drug

NV-387 has an extremely broad spectrum of antiviral activity. To date, it has been found to be highly active against every virus that we have tested in animal models:

  • NV-387 treatment was found to be able to cure lethal RSV infection in mice.
  • NV-387 treatment was substantially superior to the existing treatments, namely Tamiflu (oseltamivir) and Xofluza (baloxavir) in a lethal infection with H3N2 Influenza A virus.
  • NV-387 treatment was highly effective in an animal model for MPox using dermal orthopoxvirus infection.
  • NV-387 treatment was highly effective in an animal model for Smallpox using lethal lung infection with orthopoxvirus.
  • In addition, NV-387 treatment was highly effective in a humanized animal model (hSLAM+k.i.,InfAR-/- mice) in lethal infection with Measles virus.

Thus, NV-387, as a single drug, is responding to several unmet medical needs in viral infectious diseases at once. NV-387 is a clinical stage drug that has not been licensed or approved for any indication at present.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide ™ class of drug candidates and the nanoviricide ™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour ® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
Attn: Media Contact
NanoViricides, Inc.
1 Controls Drive, Shelton, CT 06484.
Tel: +1 (203) 937-6137.
[email protected]

Public Relations Contact:
[email protected]

Source: NanoViricides, Inc. Primary Account.

i https://www.cdc.gov/ebola/situation-summary/index.html

ii https://mpx-response.eu/a-first-safety-interim-analysis-of-mosa-shows-no-signal-of-safety-concerns-with-brincidofovir-a-potential-antiviral-to-fight-mpox/

iii According to the drug label (prescribing information), brincidofovir (“TEMBEXA”) carries a black box warning, and has warnings for elevations in hepatic transaminases and bilirubin (liver toxicity) and diarrhea and other gastrointestinal adverse events. Brincidofovir administration must be performed under physician care with continuous evaluation of liver toxicity. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf

iv https://www.cdc.gov/monkeypox/situation-summary/index.html

v Lancet Infect Dis 2025; 25: 1106-15; https://doi.org/10.1016/ S1473-3099(25)00180- X.

vi https://prvwatch.com/

vii https://bdnews24.com/health/53qusb18ga November 17, 2026.

viii NOAEL is the highest amount of drug exposure at which there are no significant increases in adverse effects compared to a control group. MTD is the highest amount of drug exposure that does not cause unacceptable side effects or overt toxicity.

ix Regeneron press release, October 26, 2026.

SOURCE: NanoViricides

Euroseas Ltd. Reports Results for the Quarter and Nine-Month Period Ended September 30, 2026, and Declares Quarterly Common Stock Dividend

logo

Research News and Market Data on ESEA

ATHENS, Greece, Nov. 17, 2026 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today its results for the three and nine-month periods ended September 30, 2026.

Third Quarter 2026 Financial Highlights:

  • Total net revenues of $54.1 million.
  • Net income attributable to controlling shareholders of $25.6 million or $3.67 and $3.65 earnings per share attributable to controlling shareholders basic and diluted, respectively.
  • Adjusted net income1 attributable to controlling shareholders for the period of $30.7 million or $4.39 and $4.37 adjusted earnings per share1 basic and diluted, respectively, which represents the net income attributable to controlling shareholders excluding the unrealized loss on investments in equity securities and the expenses incurred during the drydock of M/V “Evridiki G” prior to her sale. 
  • Adjusted EBITDA1 was $38.3 million.
  • An average of 21.0 vessels were owned and operated during the third quarter of 2026 earning an average time charter equivalent rate of $29,705 per day.
  • Declared a quarterly dividend of $0.85 per share for the third quarter of 2026 payable on or about December 16, 2026 to shareholders of record on December 9, 2026 as part of the Company’s common stock dividend plan.
  • As of November 17, 2026 we had repurchased 480,460 of our common stock in the open market, representing about 6.8% of the outstanding shares, for a total of about $11.36 million, since the initiation of our share repurchase plan of up to $20 million announced in May 2022 and renewed in July 2026.

Nine Months 2026 Financial Highlights:

  • Total net revenues of $166.4 million.
  • Net income attributable to controlling shareholders of $91.4 million or $13.10 and $13.03 earnings per share attributable to controlling shareholders basic and diluted, respectively.
  • Adjusted net income1 attributable to controlling shareholders for the period was $96.5 million or $13.84 and $13.76 adjusted earnings per share1 basic and diluted, respectively.
  • Adjusted EBITDA1 was $119.3 million.
  • An average of 21.0 vessels were owned and operated during the first nine months of 2026 earning an average time charter equivalent rate of $30,124 per day.

Recent developments:
As previously announced, the Company sold M/V “Evridiki G”, a 2,556 teu vessel built in 2001, for approximately $26 million. The vessel was delivered to her new owners, an unaffiliated third party, on October 31, 2026. The Company is expected to record a gain from the sale of approximately $22.5 million that will be accounted for in its Q4 2026 results.

Aristides Pittas, Chairman and CEO of Euroseas, commented: “We are pleased to continue reporting solid results during the third quarter of 2026 despite one of our vessels having undergone drydocking in the process of being sold. As in the first half of the year, solid contracts at highly profitable rates underpinned our profitability.

“The containership market has continued its upward climb with charter rates recording 5-10% increases for feeder sectors since the beginning of the third quarter to the middle of November 2026. Our fleet is fully chartered well into 2027, with only two vessels requiring charter renewals around the middle of the year resulting in a charter coverage of over 90% for 2027 and almost 50% for 2028 which provides significant earnings visibility and very positive cash flow.

“On the economic front, many of the factors that have shaped the first half of 2026 remain at play. In broad terms, geopolitical uncertainty continues and is increasingly becoming a “norm”. For the containership market the disruption witnessed in other areas of the logistics chain is increasing inefficiencies further despite the fact that, the situation of Suez Canal is improving and crossings are resuming.

“Another challenge for the overall containership market, this one coming from the supply side, is the high orderbook of the fleet. However, this high orderbook is mainly in the larger vessel segments, while the orderbook of the feeder and intermediate segments, in which we are active, is modest and the fleet is comparatively much older on average. This will likely result in the fleet of these segments growing very little or even decreasing in size, over the next few years, a very constructive development, for owners of such tonnage like us.

“On the investment front, we continue evaluating new opportunities to potentially complement our 12-vessel newbuilding program which we expect to be completed in early 2029. Finally, I am very pleased to announce that our Board of Directors, in continuation of its policy of rewarding shareholders with meaningful and sustainable dividends, decided to increase our quarterly dividend and declare a dividend of $0.85 per share, a $0.05 per share increase, representing an annualized yield of approximately 5% based on the recent range in which our share has traded.”

Tasos Aslidis, Chief Financial Officer of Euroseas, commented:
“In the third quarter of 2026 the Company operated an average of 21.0 vessels, versus 22.0 vessels during the same period last year. Our net revenues decreased to $54.1 million in the third quarter of 2026 compared to $56.9 million during the same period of last year, a result of the lower number of vessels operated, partly offset by the slightly increased average charter rates our vessels earned during the third quarter of 2026 compared to the same quarter of last year. At the same time, total daily vessel operating expenses, including management fees, general and administrative expenses but excluding drydocking costs, during the third quarter of 2026, averaged $7,903 per vessel per day, higher compared to $7,246 per vessel per day for the same period of last year and $7,943 per vessel per day for the first nine months of 2026 as compared to $7,386 per vessel per day for the same period of 2025. The increased operating expenses in the recent periods are mainly attributable to the higher general and administrative expenses and the higher daily vessel operating expenses.

“Adjusted EBITDA1 during the third quarter of 2026 was $38.3 million versus $38.8 million in the third quarter of last year, and $119.3 million versus $115.2 million for the respective nine-month periods of 2026 and 2025.

“As of September 30, 2026, our outstanding debt (before deducting the unamortized loan fees) was $203.6 million versus unrestricted and restricted cash of $183.3 million. As of the same date, our scheduled debt repayments over the next 12 months amounted to about $38.1 million (before deducting the unamortized loan fees).”

Third Quarter 2026 Results:
For the third quarter of 2026, the Company reported total net revenues of $54.1 million representing a 5.0% decrease from total net revenues of $56.9 million during the third quarter of 2025. On a per-vessel-per-day basis, our vessels earned a 1.4% higher average charter rate in the third quarter of 2026 as compared to the same period of 2025. The Company reported net income for the period of $25.6 million, as compared to net income of $29.7 million for the third quarter of 2025. On average, 21.0 vessels were owned and operated during the third quarter of 2026 earning an average time charter equivalent rate of $29,705 per day compared to 22.0 vessels in the same period of 2025 earning on average $29,284 per day. 

Voyage expenses, net for the third quarter of 2026 amounted to $0.3 million compared to $0.5 million in the corresponding period of 2025 and relate to owners’ expenses incurred in various ports.

Vessel operating expenses for the third quarter of 2026 amounted to $11.6 million as compared to $11.5 million for the same period of 2025. The increase mainly attributable to the increased cost of vessel supplies during the period, because of the war in the Middle East region, partly offset by the lower average number of vessels owned and operated in the third quarter of 2026, compared to the corresponding period of 2025.

In the third quarter of 2026 drydocking expenses amounted to $4.6 million as one of our vessels completed her special survey. In the corresponding period of 2025 one of our vessels completed her special survey with drydock for a total cost of $2.7 million.

Vessel depreciation for the third quarter of 2026 amounted to $6.7 million compared to $6.5 million for the same period of 2025, despite the decreased number of vessels in the Company’s fleet in the third quarter of 2026 compared to the same period of 2025 primarily reflecting the ongoing fleet renewal program, under which older vessels with lower carrying values were replaced by newer vessels with higher carrying values.

Related party management fees for the three months ended September 30, 2026, were $2.0 million at the same levels compared to the same period of 2025 due to the lower number of vessels in our fleet partly offset by the adjustment for inflation in the daily vessel management fee, effective from January 1, 2026, increasing it from 840 Euros to 875 Euros.

General and administrative expenses amounted to $1.7 million for the third quarter of 2026 compared to $1.2 million for the third quarter of 2025, due to the increased cost of our stock incentive plan and increased professional fees.

Interest and other financing costs for the third quarter of 2026 amounted to $2.2 million, compared to $3.7 million for the third quarter of 2025. This decrease is mainly due to the decreased amount of debt of our bank loans and the decreased benchmark rates of our loans in the current period compared to the same period of 2025. Capitalized interest charged on the cost of our newbuilding program was $0.2 million for the recent period versus nil for the comparative period.

For the three months ended September 30, 2025, the Company recognized a $0.01 million net gain on its interest rate swap contract, comprising $0.04 million unrealized loss from the mark-to-market valuation of our outstanding interest rate swap and a realized gain of $0.05 million. The specific contract was closed within the year 2025 and no such case existed in the third quarter of 2026.

Interest income amounted to $1.3 million for the three months ended September 30, 2026, compared to $0.9 million interest income for the same period in 2025, mainly as a result of the higher amounts of our fixed deposits and the realized coupons from investments in debt securities.

For the three months ended September 30, 2026, the Company recognized a $0.7 million unrealized loss on its investments in equity securities, resulting from a decrease in the fair value of the investments from $19.9 million as of June 30, 2026, to $19.2 million as of September 30, 2026. These investments, which had an initial cost of $20.0 million and were acquired in the first quarter of 2026 as part of the Company’s short-term cash and liquidity management strategy, are classified as investments in equity securities and measured at fair value through profit or loss in accordance with U.S. GAAP. As part of the same strategy, the Company also acquired debt securities with an initial cost of $20.0 million, classified as available-for-sale under U.S. GAAP, for which the fair value decreased from $18.9 million as of June 30, 2026, to $15.4 million as of September 30, 2026, resulting in an additional unrealized loss of approximately $3.5 million during the third quarter of 2026, which was recognized in “Other comprehensive loss”. None of these investments existed in the third quarter of 2025.

The Company reported net income for the period of $25.62 million and net income attributable to controlling shareholders of $25.64 million, for the third quarter of 2026, as compared to net income and net income attributable to controlling shareholders of $29.7 million for the same period of 2025. The net loss attributable to the non-controlling interest of $0.02 million in the third quarter of 2026 represents the loss attributable to the “Partnership”, i.e. the 49% ownership of the entity owning the M/V Thrylos represented by NRP Project Finance AS (“NRP investors”).

Adjusted EBITDA1 for the third quarter of 2026 decreased to $38.3 million compared to $38.8 million achieved during the third quarter of 2025.

Basic and diluted earnings per share attributable to controlling shareholders for the third quarter of 2026 were $3.67 and $3.65, respectively, calculated on 6,994,031 and 7,025,773 basic and diluted weighted average number of shares outstanding, compared to $4.27 and $4.25, respectively, calculated on 6,946,512 basic and 6,980,401 diluted weighted average number of shares outstanding. 

The adjusted earnings per share1 attributable to controlling shareholders for the quarter ended September 30, 2026, would have been $4.39 and $4.37 per share basic and diluted, respectively, compared to adjusted earnings per share1 basic and diluted of $4.26 and $4.23, respectively, for the quarter ended September 30, 2025. Usually, security analysts include Adjusted Net Income in their determination of published estimates of earnings per share.

Nine Months 2026 Results:
For the first nine months of 2026, the Company reported total net revenues of $166.4 million representing a 2.4% decrease from total net revenues of $170.5 million during the first nine months of 2025, mainly as a result of the decreased number of vessels owned and operated in the first nine months of 2026 compared to the corresponding period of 2025, partly offset by the increase in the average time charter equivalent rate earned by our vessels in the first nine months of 2026 compared to the same period of 2025. The Company reported net income for the period of $90.8 million, as compared to a net income of $96.5 million for the first nine months of 2025. On average, 21.0 vessels were owned and operated during the first nine months of 2026 earning an average time charter equivalent rate of $30,124 per day compared to 22.6 vessels in the same period of 2025 earning on average $28,735 per day.

Voyage expenses, net for the nine-month period of 2026 amounted to $0.7 million as compared to voyage expenses, net of $1.0 million for the same period of 2025. Voyage expenses for both periods related mainly to owners’ expenses incurred in various ports.

Vessel operating expenses for the nine-month period of 2026 amounted to $34.5 million as compared to $35.2 million for the same period of 2025. The decreased amount is mainly due to the lower average number of vessels owned and operated in the nine months of 2026 compared to the same period of 2025, partly offset by the higher daily vessel operating expenses, mainly attributable to the increased cost of vessel supplies during the period, because of the war in the Middle East region.

In the first nine months of 2026 one of our vessels completed her special survey with drydocking for a cost of approximately $4.3 million while another $0.5 million relates to supplies performed for upcoming drydocks. In the first nine months of 2025 three of our vessels completed extensive repairs afloat and one of our vessels completed her special survey with drydock for a total cost of approximately $6.2 million.

Vessel depreciation expense for the first nine months of 2026 was $20.0 million compared to $21.8 million during the same period of 2025, due to the decreased number of vessels in the Company’s fleet.

Related party management fees for the nine months ended September 30, 2026, were $5.9 million at the same levels compared to $5.9 million for the same period of 2025 due to the lower number of vessels in our fleet offset by the adjustment for inflation in the daily vessel management fee, effective from January 1, 2026, increasing it from 840 Euros to 875 Euros.

General and administrative expenses amounted to $5.1 million for the nine-month period ended September 30, 2026, as compared to $4.4 million for the same period of 2025. This increase is mainly attributable to the increased cost of our stock incentive plan and increased professional fees during the period.

During the nine-month period ended September 30, 2026, other operating expense amounted to $0.44 million and refer to expenses incurred for the formation of the Partnership of $0.60 million, partly offset by an operating income from a settlement and closure of a claim with a charterer of $0.16 million. In the nine-month period ended September 2025, other operating income amounted to $0.12 million, relating to loss of hire insurance received for one of our vessels.

The results of the Company for the first nine months of 2026 did not include any gain on sale of vessels. The results of the Company for the first nine months of 2025 included a $10.2 million gain on sale of M/V “Diamantis” that was completed in January 2025.

Total interest and other financing costs for the first nine months of 2026 amounted to $8.1 million of which $0.2 million relates to interest charged and capitalized in relation to our newbuilding program. Total interest and other financing costs for the same period of 2025 amounted to $11.7 million of which $0.1 million relates to interest charged and capitalized in relation to our newbuilding program. This decrease is due to the decreased amount of debt and the decreased benchmark rates of our loans in the current period compared to the same period of 2025.

Interest income amounted to $4.6 million for the first nine months of 2026 compared to $2.0 million interest income for the same period in 2025, mainly as a result of the higher amounts of our fixed deposits and the realized coupons from investments in debt securities.

For the nine months ended September 30, 2025, the Company recognized a $0.2 million realized gain and a $0.4 million unrealized loss for a total of $0.2 million loss on its interest rate swap contract. The specific contract was closed within the year 2025 and no such case existed in the nine months ended September 30, 2026.

For the first nine months of 2026, the Company recognized a $0.8 million unrealized loss on its investments in equity securities. This was the result of an investment in equity securities with an initial cost of $20.0 million acquired in the first quarter of 2026 and fair valued at $19.2 million as of the end of the reporting period. This investment was made as part of the Company’s short-term cash and liquidity management strategy, in the context of which the Company also acquired debt securities of initial cost of $20.0 million and fair valued at $15.4 million as of September 30, 2026, classified as available-for-sale under US GAAP, for which an unrealized loss of $4.6 million was recorded in “Other comprehensive loss” for the period. None of these investments existed in the third quarter of 2025.

The Company reported net income for the period of $90.8 million and net income attributable to controlling shareholders of $91.4 million, for the first nine months of 2026, as compared to net income and net income attributable to controlling shareholders of $96.5 million for the same period of 2025. The net loss attributable to the non-controlling interest of $0.6 million in the first nine months of 2026 represents the loss attributable to the 49% ownership of the Partnership.

Adjusted EBITDA1 for the first nine months of 2026 was $119.3 million compared to $115.2 million for the first nine months of 2025. 

Basic and diluted earnings per share attributable to controlling shareholders for the first nine months of 2026 were $13.10 and $13.03, respectively, calculated on 6,973,113 and 7,010,405 basic and diluted weighted average number of shares outstanding, compared to basic and diluted earnings per share of $13.90 and $13.84 for the first nine months of 2025, respectively, calculated on 6,939,077 basic and 6,969,992 diluted weighted average number of shares outstanding. 

The adjusted earnings per share1 attributable to controlling shareholders for the nine-month period ended September 30, 2026, would have been $13.84 and $13.76 basic and diluted, respectively, compared to adjusted earnings per share1 of $12.25 and $12.19 basic and diluted, respectively, for the same period in 2025. As mentioned above, security analysts usually include Adjusted Net Income in their determination of published estimates of earnings per share.

Fleet Profile: 

The Euroseas Ltd. fleet profile as of November 17, 2026, is as follows:


Notes:  
(*) TC denotes time charter. All dates listed are the earliest redelivery dates under each TC unless the contract rate is lower than the current market rate in which cases the latest redelivery date is assumed; vessels with the latest redelivery date shown are marked by (+).
(**) Charterer has the option to convert to a five-year charter at $32,500/day for the entire period.
(***) The entity owning the vessel under construction is 51% owned by Euroseas Ltd. and 49% by NRP Investors.

Summary Fleet Data:

(1) Average number of vessels is the number of vessels that constituted the Company’s fleet for the relevant period, as measured by the sum of the number of calendar days each vessel was a part of the Company’s fleet during the period divided by the number of calendar days in that period.

(2) Calendar days. We define calendar days as the total number of days in a period during which each vessel in our fleet was in our possession including off-hire days associated with major repairs, drydockings or special or intermediate surveys or days of vessels in lay-up. Calendar days are an indicator of the size of our fleet over a period and affect both the amount of revenues and the amount of expenses that we record during that period.

(3) The scheduled off-hire days including vessels laid-up, vessels committed for sale or vessels that suffered unrepaired damages, are days associated with scheduled repairs, drydockings or special or intermediate surveys or days of vessels in lay-up, or vessels that were committed for sale or suffered unrepaired damages.

(4) Available days. We define available days as the Calendar days in a period net of scheduled off-hire days as defined above. We use available days to measure the number of days in a period during which vessels were available to generate revenues.

(5) Commercial off-hire days. We define commercial off-hire days as days a vessel is idle without employment.

(6) Operational off-hire days. We define operational off-hire days as days associated with unscheduled repairs or other off-hire time related to the operation of the vessels.

(7) Voyage days. We define voyage days as the total number of days in a period during which each vessel in our fleet was in our possession net of commercial and operational off-hire days. We use voyage days to measure the number of days in a period during which vessels actually generate revenues or are sailing for repositioning purposes.

(8) Fleet utilization. We calculate fleet utilization by dividing the number of our voyage days during a period by the number of our available days during that period. We use fleet utilization to measure a company’s efficiency in finding suitable employment for its vessels and minimizing the amount of days that its vessels are off-hire for reasons such as unscheduled repairs or days waiting to find employment.

(9) Fleet utilization, commercial. We calculate commercial fleet utilization by dividing our available days net of commercial off-hire days during a period by our available days during that period.

(10) Fleet utilization, operational. We calculate operational fleet utilization by dividing our available days net of operational off-hire days during a period by our available days during that period.

(11) Average time charter equivalent rate, or average TCE, is a metric of the average daily net revenue performance of our vessels. Our method of calculating average TCE is determined by dividing time charter revenue and voyage charter revenue, if any, net of voyage expenses by voyage days for the relevant time period. Voyage expenses primarily consist of port, canal and fuel costs that are unique to a particular voyage, which would otherwise be paid by the charterer under a time charter contract, or are related to repositioning the vessel for the next charter. Average TCE, which is a non-GAAP metric, provides additional meaningful information in conjunction with time charter revenue and voyage charter revenue, if any, the most directly comparable GAAP measure, because it assists our management in making decisions regarding the deployment and use of our vessels and because we believe that it provides useful information to investors regarding our financial performance. Average TCE is a standard shipping industry performance metric used primarily to compare period-to-period changes in a shipping company’s performance despite changes in the mix of charter types (i.e., spot voyage charters, time charters and bareboat charters) under which the vessels may be employed between the periods. Our definition of average TCE may not be comparable to that used by other companies in the shipping industry.

(12) We calculate daily vessel operating expenses, which includes crew costs, provisions, deck and engine stores, lubricating oil, insurance, maintenance and repairs and related party management fees by dividing vessel operating expenses and related party management fees by fleet calendar days for the relevant time period. Drydocking expenses are reported separately.

(13) Daily general and administrative expenses are calculated by us by dividing general and administrative expenses by fleet calendar days for the relevant time period.

(14) Total vessel operating expenses, or TVOE, is a measure of our total expenses associated with operating our vessels. TVOE is the sum of vessel operating expenses, related party management fees and general and administrative expenses; drydocking expenses are not included. Daily TVOE is calculated by dividing TVOE by fleet calendar days for the relevant time period.

(15) Daily drydocking expenses are calculated by us by dividing drydocking expenses by the fleet calendar days for the relevant period, Drydocking expenses include expenses during drydockings that would have been capitalized and amortized under the deferral method. Drydocking expenses could vary substantially from period to period depending on how many vessels underwent drydocking during the period. The Company expenses drydocking expenses as incurred

Conference Call and Webcast: 
Later today, November 17, 2026 at 9:30 am Eastern Standard Time, the Company’s management will host a conference call to discuss the results.

Conference Call details:
Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID 13763766.Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Audio webcast – Slides Presentation:
There will be a live and then archived webcast of the conference call and accompanying slides, available through the Company’s website. To listen to the archived audio file, visit our website http://www.euroseas.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation for the third quarter ended September 30, 2026 will also be available in PDF format minutes prior to the conference call and webcast, accessible on the company’s website (www.euroseas.gr) on the webcast page. Participants to the webcast can download the PDF presentation.

About Euroseas Ltd.
Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA.

Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

The Company has a fleet of 20 vessels, including 14 Feeder containerships and 6 Intermediate containerships. Euroseas 20 containerships have a cargo capacity of 58,588 teu. After the delivery of twelve containership newbuilding containerships gradually from the third quarter of 2027 until the first quarter of 2029, Euroseas’ fleet will consist of 32 vessels with a total carrying capacity of 94,840 teu.

Forward Looking Statement
This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events and the Company’s growth strategy and measures to implement such strategy; including expected vessel acquisitions and entering into further time charters. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” and variations of such words and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to changes in the demand for containerships, competitive factors in the market in which the Company operates; risks associated with operations outside the United States; and other factors listed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. 

Visit our website www.euroseas.gr

  
Company ContactInvestor Relations / Financial Media
Tasos Aslidis
Chief Financial Officer
Euroseas Ltd.
11 Canterbury Lane,
Watchung, NJ 07069
Tel. (908) 301-9091
E-mail: [email protected]
Nicolas Bornozis
Markella Kara
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, NY 10169
Tel. (212) 661-7566
E-mail: [email protected]

View full release here.

Release – MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

Primary Logo

Research News and Market Data on MAIA

November 17, 2026 8:45am ESTDownload as PDF

MAIA advances novel telomere-targeting agent under FDA’s Fast Track designation

Further data from THIO-101 Part C may support accelerated approval filing with FDA

CHICAGO, Nov. 17, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). THIO-101 Part C is evaluating additional patients to confirm the strong efficacy data observed in Parts A and B of the study. 

The Phase 2 trial assesses advanced NSCLC patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients are treated with ateganosine 180mg followed by cemiplimab (Libtayo®) in cycles of 21 days. The sequential administration of ateganosine followed by PD-(L)1 inhibition is intended to enhance and prolong the antitumor immune response.

“It is encouraging to see an 88% disease control rate (DCR) as the THIO-101 data continue to mature. DCR serves as an excellent data surrogate for Overall Survival (OS) efficacy according to a historical meta-analysis1 and our own analysis of previous data,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, the trial’s combined study data have consistently demonstrated stable disease or better at the first tumor assessment following treatment initiation. Importantly, the Part C interim efficacy results are well aligned with the outcomes observed in Parts A and B, now across a substantially larger patient population. Consistency of the results as our patient pool expands further strengthens the compelling efficacy signals we are seeing for both of our trials in NSCLC.”

For Parts A, B, and C of THIO-101 as of October 01, 2026, the observed disease control rate (DCR) for third-line NSCLC patients resistant to chemo and immunotherapy is 88% (38 of 43 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment. This DCR measure contrasts with reported 25%–35% disease control for standard 3L chemotherapy regimens.1

MAIA has completed enrollment in Part C of its Phase 2 THIO-101 expansion, which enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and in the United States. Concurrently, an ongoing pivotal Phase 3 clinical trial of third line ateganosine treatment, THIO-104, with the same target population as THIO-101 Part C, is advancing toward regulatory milestones including 2027 interim survival analysis.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]


1 Matsumoto H, et al. Transl Lung Cancer Res 2021;10:2278–89

Primary Logo

Source: MAIA Biotechnology, Inc.

Released November 17, 2026

Release – Alliance Home Entertainment Appoints Rozita Tolouey Group Senior Vice President, Studio Strategy & Marketing

Research News and Market Data on AENT

Senior executive appointment brings extensive studio marketing, franchise development, and strategic partnership experience to AHE’s expanding home entertainment business

PLANTATION, Fla., Nov. 17, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), an entertainment commerce and collectibles platform generating more than $1 billion in annual revenue and serving more than 35,000 retail and e-commerce storefronts, today announced the appointment of Rozita Tolouey as Group Senior Vice President, Studio Strategy & Marketing of its Alliance Home Entertainment (AHE) division, adding an accomplished entertainment executive with extensive experience in studio marketing, franchise development and strategic partnerships to the company’s leadership team.

Rozita Tolouey brings more than two decades of experience across film, home entertainment and video games, including nearly 13 years at Paramount Pictures, where she served as Senior Vice President of Home Entertainment Marketing. During her tenure, she developed marketing strategies for some of the entertainment industry’s most recognizable franchises, including Mission: Impossible, Transformers, Star Trek, Teenage Mutant Ninja Turtles, SpongeBob SquarePants and G.I. Joe, alongside Marvel’s Iron Man, Iron Man 2, Thor and Captain America: The First Avenger.

Her experience also encompassed film releases and acquired and independently produced content, including Boyhood, Paranormal Activity and Nebraska. She also led the relaunch of Paramount’s home entertainment acquisitions business.

Her responsibilities spanned audience development, brand positioning, marketing strategy and campaign execution across new releases, catalog and acquired content. She worked closely with major retailers, including Walmart and Amazon, on commercial positioning, pricing, promotional strategies and product offerings. That breadth of experience across audiences, content categories and retail channels is particularly relevant as physical entertainment increasingly embraces 4K UHD, SteelBooks, limited editions and collector-focused products.

More recently, Rozita Tolouey established the Business Development & Strategic Partnerships function at Tencent Games in North America, extending her experience into building commercial relationships, strategic alliances and new business opportunities.

Building on AHE’s Home Entertainment Platform

AHE continues to build on its position as a leading home entertainment distribution and licensing partner, combining distribution scale, operational execution, retail expertise and deep studio partnerships to create new opportunities for content owners and consumers.

The company’s strategy encompasses major studio releases, catalog and deep-catalog libraries, independent films, genre entertainment and specialist collector markets. Across these categories, AHE sees continued opportunities to create value through disciplined execution, deeper consumer understanding, differentiated products and new approaches to bringing entertainment to market.

These opportunities reflect the enduring appeal of physical entertainment to consumers seeking ownership, quality, and collectible experiences. They also offer content owners new ways to extend the commercial life of their intellectual property, reach established and emerging audiences, and generate incremental value from film and television libraries.

In her new role, Rozita Tolouey will lead the strategic development of AHE’s studio partnerships, working collaboratively across the organization to identify growth opportunities, strengthen audience engagement, and develop marketing and product strategies tailored to the distinct priorities of each content owner.

“Our ambition is to be more than an exceptionally capable distribution partner. We want to help content owners build audiences, develop differentiated products and unlock greater long-term value from their film and television properties,” said Robert Oram, EVP of Alliance Home Entertainment. “Rozita brings precisely the experience, creativity and commercial understanding to help us deliver on that ambition, whether we’re working with major studios, independent filmmakers or specialist content owners.”

Rozita Tolouey sees significant opportunity in the continued evolution of physical entertainment and AHE’s ability to help partners connect content with audiences.

“Throughout my career, I’ve been passionate about connecting great entertainment with audiences in ways that create lasting value,” said Rozita Tolouey. “What excites me about AHE is the opportunity to do that across an incredibly diverse portfolio of content and partners, each with different audiences, priorities and opportunities.”

“Physical entertainment is an especially exciting space today because consumers are showing such enthusiasm for premium formats, collectible editions and the experience of owning the content they love. I’m looking forward to working closely with our partners to understand what makes their content and audiences distinctive, develop ideas that create demand and find new ways to generate incremental commercial value.”

About Alliance Entertainment

Alliance Entertainment (NASDAQ: AENT) is a premier distributor and fulfillment partner for the entertainment and pop culture collectibles industry. With more than 340,000 unique in-stock SKUs – including over 57,300 exclusive titles across compact discs, vinyl LPs, DVDs, Blu-rays, and video games – Alliance offers the largest selection of physical media in the market. Our vast catalog also includes licensed merchandise, toys, retro gaming products, and collectibles, serving over 35,000 retail locations and powering e-commerce fulfillment for leading retailers. Alliance also owns and operates proprietary collectibles brands, including Handmade by Robots™, a stylized vinyl figure line featuring licensed characters from leading entertainment franchises, and Alliance Authentic™, a premium platform for authentic, certified, and individually numbered entertainment collectibles. In addition, Alliance operates Endstate Authentic, a dedicated NFC-enabled authentication and digital product identity platform supporting authenticated collectibles, resale, and brand protection. Leveraging decades of operational expertise, exclusive sourcing relationships, and a capital-light, scalable infrastructure, Alliance connects fans and collectors to the products, franchises, and experiences they value across formats and generations.

Forward Looking Statements

Certain statements included in this Press Release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether identified in this Press Release, and on the current expectations of Alliance’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Alliance. These forward-looking statements are subject to a number of risks and uncertainties, including risks relating to the anticipated growth rates and market opportunities; changes in applicable laws or regulations; the ability of Alliance to execute its business model, including market acceptance of its systems and related services; Alliance’s reliance on a concentration of suppliers for its products and services; increases in Alliance’s costs, disruption of supply, or shortage of products and materials; Alliance’s dependence on a concentration of customers, and failure to add new customers or expand sales to Alliance’s existing customers; increased Alliance inventory and risk of obsolescence; Alliance’s significant amount of indebtedness; our ability to refinance our existing indebtedness; our ability to continue as a going concern absent access to sources of liquidity; risks that a breach of the revolving credit facility could result in the lender declaring a default and that the full outstanding amount under the revolving credit facility could be immediately due in full, which would have severe adverse consequences for the Company; known or future litigation and regulatory enforcement risks, including the diversion of time and attention and the additional costs and demands on Alliance’s resources; Alliance’s business being adversely affected by increased inflation, uncertainty regarding tariffs, higher interest rates and other adverse economic, business, and/or competitive factors; geopolitical risk and changes in applicable laws or regulations; as well as our financial condition and results of operations; substantial regulations, which are evolving, and unfavorable changes or failure by Alliance to comply with these regulations; product liability claims, which could harm Alliance’s financial condition and liquidity if Alliance is not able to successfully defend or insure against such claims; availability of additional capital to support business growth; and the inability of Alliance to develop and maintain effective internal controls.

For investor inquiries, please contact:
Dave Gentry
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

Release – Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones

Tectonic Metals Logo

Research News and Market Data on TETOF

Download the PDF

Multiple Growth Catalysts Ahead with Maiden Mineral Resource Estimate, Preliminary Economic Assessment, Resource Expansion, High-Grade Black Creek Discovery and Emerging District-Scale Targets

VANCOUVER, B.C., November 17, 2026 – Tectonic Metals Inc. (“Tectonic” or the “Company”) (TSX-V: TECT; OTCQX: TETOF) is pleased to announce the completion of its largest field program to date with a record 31,000 metres (“m”) in 170 holes drilled during the 2026 season at the Company’s flagship 99,840-acre Flat Gold Project (“Flat”) in southwest Alaska, U.S.

The record program, representing a 70% increase in metres drilled year-over-year, comprised 55 diamond and 115 reverse circulation (“RC”) holes to support Tectonic’s five strategic pillars set at the outset of 2026. Through targeted drilling and exploration, technical studies, site readiness, and close collaboration with local partners and stakeholders, the Company made significant progress across all areas designed to drive shareholder value and position Flat for a transformational 2027:

  1. Chicken Mountain expansion and growth
  2. District-scale regional discovery and drilling
  3. Maiden Mineral Resource Estimate (“MRE”) targeted for Q1 2027
  4. Project de-risking and infrastructure expansion
  5. Preliminary Economic Assessment (“PEA”) targeted for Q2 2027

Maggie Layman, Vice President, Exploration, commented:

“2026 has been a defining year for Tectonic and our flagship Flat Gold Project with a record 31,000 m drilled in 170 holes, putting us on track to deliver our maiden Mineral Resource Estimate and Preliminary Economic Assessment in 2027. Our exploration efforts have also increased our geological understanding of a significant gold system, intersecting high-grade gold at Chicken Mountain, Alpha Bowl and Black Creek, while generating new targets across the Flat district.

“Beyond drilling, we demonstrated our builders’ mindset, investing heavily in infrastructure and upgrades to our camp, roads, airstrip and equipment. These improvements will strengthen our operational capacity, support longer field seasons and lay the groundwork for eventual year-round operations in Alaska.”

“None of this would have been possible without our team’s steadfast commitment to health, safety and environmental responsibility. We are incredibly proud of what we accomplished and are grateful for the hard work and dedication of our employees, contractors, Doyon and local partners, whose collective efforts made this year a success.”

Advancing the 2026 Five Pillars of Growth

1. Chicken Mountain Expansion and Growth Drilling

Chicken Mountain was the primary focus of the 2026 drill program, accounting for the majority of the 31,000 m drilled across 170 holes, primarily dedicated to resource delineation and expansion ahead of the planned maiden MRE. The program also included step-outs along strike, width and depth, as well as targeted drilling to expand higher-grade corridors and evaluate potential starter pits:

  • Defined footprint: Drilling has defined continuous mineralization extending 3.3 kilometres (“km”) along strike, 700 m in width and to a vertical depth of 300 m. The system remains open in all directions (see Figures 1 and 2).
  • Newly recognized style of mineralization: Drilling at the Adit Zone, a priority gold-bearing corridor at Chicken Mountain, identified mineralization associated with previously unrecognized hydrothermal breccias and intrusive contacts. This has expanded Tectonic’s understanding of the controls on mineralization, with assays pending for follow-up holes drilled at 100 m spacing to test the breccia’s extent.
  • High-grade corridors for future starter pit evaluation: A near-surface intercept at Alpha Bowl, the northern extension of Chicken Mountain, returned 2.41 grams per tonne gold (“g/t Au”) over 59.44 m including 11.82 g/t Au over 10.67 m (see press release dated October 15, 2026). The hole ended in mineralization, leaving the intersection open for follow-up drilling. Together with higher-grade intervals and at- or near-surface mineralization at Adit Zone, results to date support further evaluation of potential starter-pit opportunities across both areas.

2. District Scale Regional Discovery and Drilling

Drilling conducted during the year also provided evidence of a second gold system within the Flat district. Together with a comprehensive regional soil sampling program, this work will help define future drill targets and further expand the Company’s exploration pipeline:

  • Black Creek high-grade discovery with significant untested potential: Drilling from the 2025 and 2026 programs intersected gold mineralization in 17 of 18 holes at Black Creek, highlighted by CMR26-159, which returned 5.61 g/t Au over 41.15 m (see press release dated November 2, 2026). Over 85% of Black Creek’s 1,500 m x 700 m gold-in-soil anomaly remains untested and is situated within a larger 1.5 km x 2.5 km geophysical anomaly interpreted to represent an intrusive centre. Black Creek has become a high-priority target, with additional drilling planned to evaluate its potential to host a mineral resource at Flat.
  • Regional exploration opportunity: A regional soil sampling program was carried out across Black Creek, Caribou, Jam, Horseshoe, and Chicken Mountain South and East (see Figure 3). Results from pending assays will be integrated with geological and geophysical datasets to refine interpretations and advance high-priority targets toward drill readiness in 2027.

3. Maiden Mineral Resource Estimate (Q1 2027)

Compilation of all technical datasets has been completed and approximately 50,000 m of the Company’s total drilling at Chicken Mountain is expected for inclusion in the upcoming maiden MRE. Work is progressing across two key fronts:

  • Geological modelling: The structural, lithological and geochemical data collected in 2026 have significantly advanced the understanding of the mineralization’s geometry, continuity and controls, which will inform resource domains and grade continuity, as well as highlight opportunities for future resource growth.
  • Independent Qualified Person (“QP”) retained: The Company has engaged an independent QP to oversee and author the MRE, with a formal site visit completed and resource modelling work progressing on schedule.

4. Project De-risking and Infrastructure Expansion

Tectonic continues to systematically advance Flat from exploration toward district-scale development, investing in infrastructure, environmental programs and early permitting aimed at reducing risk and increasing operational efficiency:

  • Permitting: Continued proactive regulatory and stakeholder engagement activities to support future exploration and development.
  • Environmental programs: Advanced baseline studies, including fish and wildlife monitoring, environmental data collection and regulatory planning.
  • Infrastructure expansion: Made significant investments in camp and site infrastructure to support expanded field activities and position the project for eventual year-round operations. The Company utilized the airstrip located directly on the property to mobilize heavy machinery for road access improvements and acquired fuel trucks for on-site fuel supply. These investments will improve operational efficiency, streamline site logistics and help reduce operating costs going forward. A brand-new camp was also built alongside the existing facilities, expanding overall capacity to support a larger workforce and accommodate the anticipated growth in future project activities.

5. Preliminary Economic Assessment (Q2 2027)

Tectonic’s 2026 field program was designed not only to support the Company’s maiden MRE, but also to advance the Flat Gold Project toward its first PEA, targeted for Q2 2027. Throughout the season, the Company advanced and completed several key technical studies in support of these initiatives:

  • Geotechnical studies: Completed two geotechnical drill holes to advance pit slope design, hydrogeological characterization and preliminary mine planning. Initial Acid Base Accounting (“ABA”) and waste rock characterization work was also initiated.
  • Metallurgical testing: Advanced the Company’s 15-column heap leach test program, evaluating coarser crush sizes and potential run-of-mine (“ROM”) processing scenarios. The program builds on previously reported gold recoveries of 96% and 91% from 0.75-inch (3/4”) crushed material (see press release dated September 19, 2024).
  • Study initiation: The Company is finalizing the engagement of an independent consulting team to prepare for the PEA.

Partnership with Doyon

Tectonic continued to work closely with Doyon, Limited (“Doyon”), an Alaska Native Regional Corporation and principal landowner at Flat, as well as a major shareholder of the Company. This partnership remains central to Tectonic’s commitment to responsible exploration, local participation and long-term value creation in the region.

Local participation was a focus throughout the 2026 field season, with approximately 25% of the field workforce identifying as Alaska Native, including Doyon shareholders.

Through regular engagement, collaboration, and shared project objectives, Tectonic and Doyon continue to work together to advance Flat in a manner that supports both project success and long-term regional benefits.

Multiple Milestones and Catalysts Ahead

During 2026, Tectonic expanded its team across multiple disciplines, strengthening expertise in exploration, operations, permitting, stakeholder engagement and corporate leadership, enabling the Company to successfully deliver a program of this scale while maintaining a disciplined and focused approach to project advancement. With field operations now concluded, the Company is anticipating a large volume of technical data to support a series of near-term milestones and catalysts through the first half of 2027:

  • Robust assay pipeline ahead: With roughly 25,000 m of drilling from over 120 holes currently pending assays, a steady stream of results is expected through the end of the year and into early 2027.
  • Metallurgical results: Test results from 15 heap leach columns at Chicken Mountain are expected by the end of November.
  • Resource and economic studies: A maiden MRE targeted for Q1 2027, followed by a PEA targeted for Q2 2027.
  • District expansion: Regional soil sampling, geological mapping and other datasets will be integrated to refine and prioritize targets across the Flat district.
  • 2027 planning: Exploration and project advancement plans are currently underway for the 2027 field season.

Multimedia and Videos

  • Watch Tectonic’s year-end video highlighting the 2026 season at Flat here.
  • View supplemental maps and figures here.

Figure 1: 2026 Collar Locations at Chicken Mountain

Figure 2: Tectonic Metals Drilling Through Time Plan View and Long Section

Figure 3: Soil Sample Location Map

Qualified Person   

Tectonic Metals’ disclosure of technical or scientific information in this press release has been reviewed, verified and approved by Peter Kleespies, M.Sc., P.Geo., Chief Geological Officer, who is a Qualified Person in accordance with Canadian regulatory requirements set out in National Instrument 43-101.  

Analytical work for the 2026 Flat project drilling program was performed by ALS Global (“ALS”), an internationally recognized and accredited laboratory independent of Tectonic. On-site, core and reverse circulation samples were sealed in security-tagged bags and shipped under strict chain-of-custody protocols to the Lynden Transport logistics operator in Anchorage, Alaska, for delivery to ALS facilities in Vancouver, British Columbia.

Upon arrival at the laboratory, samples were dried, crushed to 2 mm and riffle split into nominal 500-gram subsample aliquots (prep codes CRU-31, SPL-32a). One portion was analyzed for gold using PhotonAssay™ (ALS code Au-PA01). PhotonAssay™ uses high-energy X-rays to determine gold content from a large sample aliquot, typically 500 g of crushed material. The method is non-destructive and is particularly suited to gold systems where larger sample aliquots may improve representativity. If additional nominal 500-gram PhotonAssay™ analysis splits are conducted for a given sample, results from all splits are combined on a weighted-average basis. A second portion was pulverized such that 85% of the sample passed 75 µm (PUL-31) and was analyzed by four-acid digestion with ICP-MS finish for 48 elements (ME-MS61), along with aqua regia digestion with ICP-MS finish for trace levels of mercury (Hg-MS42).

Quality assurance and quality control (QA/QC) protocols included the insertion of certified reference material every 20 samples, blank samples at a rate of one in every 25 samples and field duplicate samples (split from the original 1.5 m for RC or core sample intervals) every 25 samples. All QA/QC results returned values within acceptable limits.

About Tectonic Metals Inc.

Tectonic Metals Inc. is a mineral exploration company focused on exploring and developing its flagship Flat Gold Project in southwestern Alaska, covering 99,840 acres of predominantly Native-owned land belonging to Doyon, Limited, a leading Alaska Native Regional Corporation and one of Tectonic’s largest shareholders. The current focus is on advancing the Chicken Mountain target, one of six multi-kilometre-scale intrusion zones at the Flat Gold Project, towards the Company’s maiden Mineral Resource Estimate in Q1 2027 and Preliminary Economic Assessment in Q2 2027.

Founded by key members of the Kaminak Gold team behind the discovery and advancement of the Coffee Gold Project, which was acquired by Goldcorp for $520 million in 2016, Tectonic brings a proven track record in exploration, project advancement, capital markets and value creation. Collectively, the team has helped identify more than 40 million ounces of gold, advanced 20 projects through to feasibility, permitted 25 projects, completed over $6 billion in mergers and acquisitions and raised more than $6 billion in capital.

Tectonic’s mission is to be a shift in the game: working for our shareholders and the communities where we operate, putting people first, playing big and staying true to our word every step of the way.

On behalf of Tectonic Metals Inc.,  

Tony Reda, President and Chief Executive Officer  

For further information about Tectonic Metals Inc. or this news release, please visit our website at www.tectonicmetals.com or contact: Keren Yun, Vice President, Investor Relations
1-888-685-8558 or [email protected]

Cautionary Note Regarding Forward-Looking Statements, Historical Information and Visual Observations

This news release contains “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements herein that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often, but not always, identified by words such as “may,” “will,” “should,” “anticipate,” “believe,” “expect,” “intend,” “plan,” “estimate,” “potential,” “target,” or similar terminology, or that events or conditions “may” or “will” occur.

Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for mineralization at Tectonic’s projects; the nature, scope and timing of future exploration activities and programs; the timing and completion of the Company’s maiden Mineral Resource Estimate and Preliminary Economic Assessment; the timing and receipt of pending assay results from the 2026 exploration program; the timing and results of metallurgical testing; the interpretation of geological observations; the possible size or scale of mineralized systems; the receipt of regulatory approvals, and the anticipated benefits of current and future exploration programs.

This release may also refer to historical information, including results from past exploration activities and placer production figures. Any such historical information has not been independently verified by Tectonic, may not be reliable, and should not be relied upon as current, NI 43-101 compliant data.

In addition, this release may contain detailed geological notes, and descriptive observations such as alteration styles, mineralogy and visible gold. These observations are preliminary in nature, may not be representative of the entire interval or system, and should not be relied upon as a guarantee of mineralized assay results or as the basis for any investment decision. Investors and readers are cautioned that visual estimates, core photographs, and geological descriptions are not substitutes for laboratory assay results and do not demonstrate the economic viability of any mineral deposit.

Forward-looking statements are not guarantees of future performance. They are based on a number of assumptions made as of the date such statements are provided, including, among others: assumptions regarding future gold and other metal prices; currency exchange and interest rates; favourable operating and political conditions; timely receipt of permits and regulatory approvals; availability of labour, equipment, and services; stability of financial and capital markets; availability of financing on acceptable terms; accuracy of exploration data and geological models; and the ability to successfully advance planned exploration programs. Many of these assumptions are beyond the control of Tectonic and may prove to be incorrect.

Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. These risks include, without limitation: risks inherent to mineral exploration and development; volatility of commodity prices; changes in laws, regulations, and policies; delays or inability to obtain required approvals and permits; availability of financing; general economic, political, and market conditions; labour disputes and shortages; equipment and supply risks; environmental and social risks; competition; inaccuracies in exploration results or geological interpretations; and other risks detailed from time to time in the Company’s continuous disclosure filings.

Although management believes the expectations expressed in such forward-looking statements are reasonable as of the date made, there can be no assurance they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements, historical information, or preliminary visual geological observations. Actual results and future events may differ materially from those anticipated. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Tectonic disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Release – Bimergen Energy Reports $3.0 Million Revenue and $2.4 Million Net Income for Q3

Bimergen Energy Corporation IR Overview

Research News and Market Data on BESS

November 17, 2026 6:30am EST

  • Third-quarter revenue reached $3.0 million, compared with no revenue in the prior-year period; nine-month revenue totaled $10.9 million, compared with no revenue in 2025.
  • Net income improved $4.2 million year over year to $2.4 million, compared with a net loss of $1.8 million in the prior-year period.
  • Third-quarter Adjusted EBITDA totaled $3.0 million, marking the Company’s second consecutive quarter of positive Adjusted EBITDA.
  • Cash and cash equivalents of $7.8 million at September 30, 2026, with working capital of $8.8 million, an improvement of $13.3 million from year-end 2025.

NEWPORT BEACH, CA, Nov. 17, 2026 (GLOBE NEWSWIRE) — Bimergen Energy Corporation (NYSE American: BESS) (“Bimergen”), a U.S.-based developer, owner and operator of battery energy storage infrastructure, today announced financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Revenue of $3.0 million, compared with no revenue in the prior year period.
  • Gross profit of $0.7 million, compared with no gross profit in the prior year period.
  • Net income improved $4.2 million year over year to $2.4 million, $0.33 earning per share, compared with a net loss of $1.8 million in the prior-year period.
  • Net income improved 50% from the prior 2026 quarter, second quarter $1.6 million to third quarter $2.4 million net income.
  • Third quarter Adjusted EBITDA totaled $3.0 million
  • $40.5 million total assets and $36.1 million stockholders’ equity at September 30, 2026 with 7.4 million fully diluted shares.

Second and Third Quarter 2026 Financial Highlights

  • Bimergen reported $10.9 million in combined revenue for the second and third calendar quarters, $5.5 million gross profit or 50.5%, with net income of $4.1 million, $0.55 per share for these first two full quarters after uplist to the NYSE-American in February 2026.
  • The total adjusted EBITDA for the second and third calendar quarters was $6.9 million, $0.93 earnings per share.

The results reflect Bimergen’s progress in transitioning its approximately 2.0-gigawatt (GW) battery energy storage development pipeline into revenue-generating transactions. Through the first nine months of 2026, the Company generated $10.9 million in revenue. Bimergen reported $3.0 million in Adjusted EBITDA for the third quarter, marking its second consecutive quarter of positive Adjusted EBITDA as it begins monetizing its development portfolio.

Bimergen ended the third quarter with working capital of approximately $8.8 million, compared with a working capital deficit of $4.5 million at December 31, 2025. The $13.3 million improvement reflects a strengthened financial position as the Company advances its battery energy storage development portfolio.

Financial Results Driven by Pipeline Conversion

During 2026, Bimergen completed transactions involving three battery energy storage projects in Texas’ ERCOT market, representing a combined 480 megawatt-hours (MWh) of planned capacity. The transactions contributed to the Company’s reported revenue and demonstrated its ability to convert development activity into financial results while retaining a 7.5% equity interest in the projects.

Bimergen’s business model is designed to create value by developing battery energy storage projects (battery farms), securing project-level institutional capital partners and monetizing projects as they advance toward commercial operation. This approach enables the Company to generate revenue at key development milestones while retaining equity interests that provide participation in the assets’ potential long-term value.

As Bimergen advances its development pipeline, quarterly revenue will vary based on the timing of project transactions. The Company’s focus is on building a steady flow of monetization opportunities across its growing portfolio and achieving consistent revenue from quarter to quarter is expected in the years to come as projects become operational. Once operational, the battery storage projects are expected to generate revenue primarily by purchasing power at lower prices and selling it back to the grid at higher prices.

“2026 marks an important turning point for Bimergen as we begin translating our development pipeline into financial results,” said Bob Brilon, Co-Chief Executive Officer of Bimergen Energy. “Our initial project transactions validate our approach, and with a substantial portfolio of battery storage development projects, we see significant opportunities to build on our progress.”

Positioned for Continued Portfolio Monetization

Bimergen has assembled a diversified development pipeline of approximately 2.0 GW across 33 battery energy storage projects in major U.S. electricity markets, including ERCOT, PJM, WECC and MISO. The portfolio includes the Company’s Redbird project near Houston, Texas, with planned capacity of 100 megawatts (MW) and 400 MWh, as well as a growing portfolio of distributed energy storage projects.

“With projects at various stages of development, Bimergen is positioned to pursue additional monetization opportunities as its portfolio advances toward commercialization,” said Cole Johnson, Co-Chief Executive Officer of Bimergen Energy. The Company’s established capital relationships and initial project transactions provide a foundation for expanding these activities across its broader development pipeline.

About Bimergen Energy Corporation

Bimergen Energy Corporation (NYSE American: BESS) is a U.S.-based energy infrastructure developer, asset owner, and operator focused on utility-scale and distributed battery energy storage systems (BESS). The Company develops projects designed to enhance grid reliability, support renewable energy integration, and provide flexible energy solutions across key U.S. power markets. Bimergen works with technology providers and capital partners to advance projects through development, construction, and long-term operation. For more information about Bimergen Energy, please visit www.bimergen.com.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Bimergen Energy Corporation’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 31, 2026, and in its subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Bimergen Energy Corporation undertakes no duty to update such information except as required under applicable law.

For Further Information Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
[email protected]

Primary Logo

Source: Bimergen Energy Corporation

Released November 17, 2026

Release – Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

logo

Research News and Market Data on GLSI

November 17, 2026 06:00 ET  | Source: Greenwich LifeSciences, Inc.

STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations.

The SABCS 2026 will be held from December 8-11, 2026. The posters will be presented on December 9, 2026 during the poster sessions for ongoing clinical trials and late breaking abstracts, with both posters being authored by the Steering Committee of FLAMINGO-01.

The posters will be provided on the Company’s website during the conference when permitted to do so by SABCS. In addition, the following has been updated on the Company’s website: Corporate slides, FLAMINGO-01 Phase III trial design, corporate presentation from investor conference, fireside chat, analyst commentary, interview which aired on Bloomberg/CNBC TV, and a patient and doctor interview at a clinical site participating in FLAMINGO-01.

About SABCS

The 49th annual SABCS has grown to be the industry’s premier breast cancer conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world. Approximately 10,000 health care professionals from more than 105 countries are expected to attend in 2026. For more information, please visit the conference website at: https://www.sabcs.org/

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Release – T3 Defense Completes First Aerostat Surveillance Deployment at Mexican Federal Prison Facility

Research News and Market Data on DFNS

KeepZone-led transaction to secure a CEFERESO federal prison delivers RT Aerostat System, with potential expansion to additional facilities

November 16, 2026 09:10 ET  | Source: T3 Defense Inc.

Share

NEW YORK and NETANYA, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses involved in national security programs, today announced that its subsidiary, KeepZone AI Inc. (“KeepZone”), has completed the delivery, installation and activation of an aerostat surveillance system manufactured by RT LTA Systems Ltd. (“RT”) at a Centro Federal de Readaptación Social (Federal Social Readaptation Center, “CEFERESO”), part of Mexico’s federal prison system.

KeepZone, which was acquired by T3 Defense on November 4, 2026, is RT’s representative in Mexico, and secured the sale and managed the deployment. RT, based in Yavne, Israel, has designed and manufactured tactical aerostat systems since 1996, with systems in service with military, police and border-security users worldwide, including in Mexico.

T3 Defense Completes First Aerostat Surveillance Deployment at Mexican Federal Prison Facility

The system is now operational and provides the facility with persistent, elevated perimeter and area surveillance. The tethered aerostat, secured to a ground-based mooring system by a tether cable, carries an advanced electro-optical/infrared (EO/IR) observation payload and is capable of remaining airborne for up to 72 consecutive hours. The project marks the first installation under the program and includes operator training and ongoing on-site support, with the potential to expand to additional federal prisons and other high-security facilities in Mexico.

KeepZone’s Role as T3 Defense’s HLS Commercial Platform

KeepZone serves as T3 Defense’s dedicated homeland security (HLS) marketing, sales and business development platform. As RT’s representative in Mexico, KeepZone originated, structured and led the transaction, coordinated delivery and installation, and is supporting the customer through training and initial operations. The deployment demonstrates KeepZone’s ability to convert its Latin American channels into executed, operational programs with government end users.

“This deployment is exactly why we brought KeepZone into the T3 Defense portfolio,” said Menny Shalom, Chairman and Chief Executive Officer of T3 Defense. “KeepZone identified the requirement, led the transaction and delivered an operational system to a federal government customer in Mexico. Securing correctional facilities is a demanding, persistent mission, and a successful first installation gives us a strong reference point as we pursue additional facilities. It also validates KeepZone’s Latin American channel as a route to market for the broader T3 Defense portfolio, including our subsidiaries’ counter-drone, command-and-control and sensor-mast capabilities.”

“Completing the supply, installation and activation of this system is a significant milestone for KeepZone in Mexico,” said Alon Dayan, Chief Executive Officer of KeepZone. “Our team worked closely with RT and the customer from requirement definition through training and go-live. With the system now operating, our focus is on supporting the customer’s operations and on the opportunity to extend this capability to additional federal prisons and high-security facilities.”

Portfolio Context

T3 Defense continues to position its operating subsidiaries, including Rimon, Positech, Tiltan, Nimbus and KeepZone, across the mission-critical hardware, software and systems used in defense, homeland security and counter-drone programs. KeepZone complements the Company’s engineering and manufacturing subsidiaries with a dedicated commercial platform serving critical infrastructure, law enforcement, public safety, correctional and border security customers in Israel, North America, Latin America and the Gulf.

About KeepZone AI Inc.

KeepZone AI Inc. is a homeland security technology company that markets, integrates and supports a multi-vendor portfolio of screening, surveillance, counter-UAS, AI analytics and unmanned aerial solutions for critical infrastructure, government and high-security environments. For more information, visit www.KeepZone.ai.

About T3 Defense Inc.

T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity- and resource-constrained, in specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value. For more information, visit www.t3dfns.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the performance and continued operation of the system described herein; the potential expansion of the program to additional federal prisons or other facilities in Mexico or elsewhere; the potential for follow-on, recurring or additional orders from the customer or other parties; KeepZone’s representation and distribution relationships, including with RT; the potential for cross-selling of the Company’s subsidiaries’ products through KeepZone’s channels; and the Company’s growth and acquisition strategy. These statements are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including: the risk that a single deployment is not indicative of future orders or of participation in any broader program; the absence of any assurance that the program will be expanded to additional facilities; dependence on government customers, public procurement processes, budgets and political conditions in Mexico; the risk that KeepZone’s representation or distribution agreements, including with RT, are terminated or not renewed; dependence on third-party manufacturers for product performance, delivery and support; export-control, licensing and regulatory requirements; currency and payment-collection risks associated with international customers; integration risks related to the acquisition of KeepZone; competitive and geopolitical conditions, including conditions in Israel; the Company’s liquidity and capital resources; the Company’s ability to maintain compliance with Nasdaq listing requirements; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contact Us:

T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

KeepZone AI Inc.
1200 Fuller RD,
Linden 07036, NJ, USA
[email protected]


Investor Relations

The Equity Group Inc.
Lena Cati
[email protected]
+1 212 836-9611
Val Ferraro
[email protected]
+1 212 836-9633

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bcd6a668-3de2-4c8a-9016-c9034033d826

Release – Superior Group of Companies Reports Third Quarter 2026 Results

Research News and Market Data on SGC

Total net sales of $146.0 million, up 5% over prior year third quarter
Net income of $2.6 million versus $2.7 million in prior year third quarter
Adjusted EBITDA of $6.7 million versus $7.5 million in prior year third quarter
Tightens full-year Outlook

ST. PETERSBURG, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its third quarter 2026 results.

“We drove solid overall top line growth from continued momentum in our Branded Products and Contact Centers segments,” said Michael Benstock, Chief Executive Officer. “New leadership in Healthcare Apparel continues to execute toward a more focused product strategy to improve margins and reduce working capital requirements in the quarters ahead. On a consolidated basis, we were able to hold EPS essentially flat versus the prior year quarter despite incremental charges associated with our strategic shift in Healthcare Apparel. We look forward to finishing the year with growth in both sales and earnings compared to 2025, and with a solid balance sheet that provides the foundation for continued strategic investment such as our recent acquisition of Select VoiceCom and the return of capital to shareholders.”

Third Quarter Results

For the third quarter ended September 30, 2026, net sales were $146.0 million, up 5% from third quarter 2025 net sales of $138.5 million. Net income was $2.6 million or $0.17 per diluted share compared to net income of $2.7 million or $0.18 per diluted share for the third quarter of 2025.

2026 Full-Year Outlook

The Company tightened its full-year 2026 net sales forecast to a range of $578.0 million to $585.0 million, from its previous range of $572.0 million to $585.0 million, up from 2025 net sales of $566.2 million. It also tightened its full-year adjusted earnings per diluted share forecast to a range of $0.60 to $0.66, from its previous range of $0.54 to $0.66, up from $0.46 in 2025 and representing 43% growth at the high end.

Webcast and Conference Call

The Company will host a webcast and conference call at 8:00am Eastern Time today. The live webcast and archived replay can be accessed in the investor relations section of the Company’s website at https://ir.superiorgroupofcompanies.com/Presentations. Interested individuals may also join the teleconference by dialing 1-844-861-5505 for U.S. dialers and 1-412-317-6586 for international dialers. The Canadian toll-free number is 1-866-605-3852. Please ask to be joined to the Superior Group of Companies call. A telephone replay of the teleconference will be available through November 23, 2026. To access the replay, dial 1-855-669-9658 in the United States or Canada, or 1-412-317-0088 from international locations. Please reference conference number 8522694 for replay access.

Disclosure Regarding Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements“ intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential,“ or “plan“ or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements in this press release include 2026 guidance of net sales and earnings per diluted share and may also include, without limitation: (1) projections of revenue, income, and other items relating to our financial position and results of operations, including short term and long term plans for cash, (2) statements of our plans, objectives, strategies, goals and intentions, (3) statements regarding the capabilities, capacities, market position and expected development of our business operations and (4) statements of expected industry and general economic trends.

Such forward-looking statements are subject to certain risks and uncertainties that may materially adversely affect the anticipated results. Such risks and uncertainties include, but are not limited to, the following: the impact of competition; the impact of global conflicts, such as the Russia-Ukraine War and the joint U.S.-Israeli War with Iran in 2026, oil and natural gas prices, uncertainties related to tariffs, duties, trade wars and related matters, supply disruptions, inflationary environments (including with respect to shipping costs and the cost of finished goods and raw materials), employment levels (including labor shortages), and general economic and political conditions in the areas of the world in which the Company operates or from which it sources its supplies or the areas of the United States of America (“U.S.“ or “United States“) in which the Company‘s customers are located; changes in the healthcare, retail chain, food service, transportation and other industries where uniforms and service apparel are worn; our ability to identify suitable acquisition targets, discover liabilities associated with such businesses during the diligence process, successfully integrate any acquired businesses, or successfully manage our expanding operations; the price and availability of raw materials; attracting and retaining senior management and key personnel; the Company’s ability to maintain effective internal control over financial reporting; and other factors described in the Company‘s filings with the Securities and Exchange Commission (“SEC”), including those risks described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 entitled “Risk Factors” and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements made herein and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and we disclaim any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as may be required by law.

About Superior Group of Companies, Inc. (SGC):

Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers, each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. We are committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit www.superiorgroupofcompanies.com.

Investor Relations Contact:
[email protected]

View full release here: Superior Group of Companies Reports Third Quarter 2026 Results – Superior Group of Companies

Release – Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc

Research News and Market Data on UNCY

November 16, 2026 7:05am EST Download as PDF

Related Documents

10-QFiling

PDF HTML

XBRL

ZIP HTML

  • New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027
  • As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $59 million, with expected runway beyond 2027, including the cost of potential OLC launch

MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

Key Highlights & Upcoming Milestones

  • OLC NDA Resubmission: In October, the Company announced that the FDA has accepted the resubmission of its NDA for OLC and set a PDUFA target action date of March 25, 2027. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026, which cited deficiencies previously identified at the original Drug Product (DP) vendor. The June 2026 CRL did not raise concerns regarding clinical efficacy or safety data or request additional data from the Company. The resubmitted NDA remains subject to FDA review.
    • The NDA resubmission includes CMC data from a new DP manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status. The Company does not know whether the FDA will decide to conduct a pre-approval inspection of this DP vendor.
    • The original DP vendor was recently inspected by the FDA. If the FDA finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to align with the FDA on whether that determination could shorten its review timeline and potential approval.
  • Commercial Readiness: In preparation for the potential launch of OLC, Unicycive continues to advance its commercial readiness initiatives:
    • Discussions with dialysis organizations as part of the OLC launch planning.
    • The Company is in active discussions with key commercial leaders, with plans to bring them on board in the first quarter of 2027 and, if OLC is approved by the FDA, expects to hire an optimized sales force to target the physician prescriber base.
    • Unicycive is also focused on optimizing patient access across all reimbursement settings and plans to provide dedicated access and services through its UniSource™ support hub.
      On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule, establishing permanent phosphate binder funding within the dialysis bundled payment through a $12.85 per-treatment addition to the base rate effective January 1, 2027, following the expiration of separate transitional payments for existing binders. CMS also finalized a hyperphosphatemia clinical quality measure beginning with payment year 2029, based on 2027 performance, reinforcing the importance of sustained phosphorus control. Unicycive believes that these changes create favorable commercial launch conditions for OLC, if approved. Subject to FDA approval and CMS confirmation of Transitional Drug Add-on Payment Adjustment (TDAPA) eligibility, OLC could potentially qualify for two years of separate reimbursement at 100% of average sales price while dialysis providers continue to receive the new funding for binders embedded in the base rate.
  • TDAPA Eligibility: Unicycive believes OLC meets the criteria for the TDAPA upon FDA approval:
    • OLC qualified for a 505(b)(2) regulatory path because it contains an active moiety (lanthanum) that was previously approved; however, OLC contains a new active ingredient, oxylanthanum carbonate, that was not previously approved. The Company believes this supports Type 2 NDA classification under the FDA’s Manual of Policies and Procedures 5018.2, NDA Classification Codes.
    • The determination of OLC’s NDA classification rests solely with the FDA and remains subject to the agency’s determination of NDA classification at the time of approval. The Company believes OLC, if approved, would qualify for TDAPA, subject to meeting applicable CMS requirements.

Financial Results for the Quarter Ended September 30, 2026

Research and Development (R&D) expense was $2.2 million for the quarter ended September 30, 2026, compared to $3.0 million for the three months ended September 30, 2025. The decrease was primarily driven by a $1.2 million decrease in developments costs, which was partially offset by an increase in non-cash stock-based compensation of $0.5 million.

General and Administrative (G&A) expense was $6.6 million for the quarter ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily driven by a $0.6 million increase in non-cash stock-based compensation as well as an increase of $0.2 million in other labor costs. There was also an increase of $1.4 million related to commercial launch preparation.

Other income (expense) was $1.8 million for the quarter ended September 30, 2026, compared to $1.3 million income for the three months ended September 30, 2025, attributed primarily to the change in fair value of the Company’s warrant liability.

Net loss attributable to common stockholders, basic and diluted, for the quarter ended September 30, 2026, was $(7.0) million, or $(0.25) per share of common stock, compared to $(6.0) million, or $(0.33) per share of common stock, for the three months ended September 30, 2025. The increased net loss for the quarter ended September 30, 2026, was attributed primarily to an increase in commercial launch expenses.

Cash, cash equivalents and marketable securities were approximately $59 million as of September 30, 2026, with expected runway beyond 2027, including anticipated increased expenses related to the launch of OLC should it receive approval.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:
Unicycive Therapeutics
[email protected]

SOURCE: Unicycive Therapeutics, Inc.

View full release here.

Release – Aurania Intersects 10.10 g/t Gold over 4.15 Metres in Initial Drill Results from the Thormodsdalur Gold Project in Iceland

Aurania Resources Ltd.

Research News and Market Data on AUIAF

Twin hole TARU2026-05 includes 15.31 g/t gold over 2.40 metres; geological observations point to further potential at depth

November 16, 2026 1:00 AM EST | Source: Aurania Resources Ltd.

Toronto, Ontario–(Newsfile Corp. – November 16, 2026) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) is pleased to report initial assay results from the first two holes of its 2026 drill program on the Thormódsdalur epithermal gold-silver project in Iceland (the “Project”). Hole TARU2026-05 intersected 10.10 grams per tonne (“g/t”) gold (“Au”) over 4.15 metres from 20.85 m downhole, including 15.31 g/t Au over 2.40 metres. Hole TARU2026-04 intersected two gold-bearing zones: 3.13 g/t over 2.50 metres from 54.50 m downhole, including 4.41 g/t Au over 1.60 metres and 2.05 g/t Au over 4.30 metres (from 65.85 m, including 4.75 g/t over 1.35 metres). Both holes were drilled to twin historical intersections and assess gold grades using improved core recovery.

Highlights

  • TARU2026-05: 10.10 g/t Au over 4.15 metres from 20.85 metres downhole, including 15.31 g/t Au over 2.40 metres, in quartz veining and vein-bearing fault breccia at shallow depth.
  • TARU2026-04: two gold-bearing zones, returning 3.13 g/t Au over 2.50 metres from 54.50 metres (including 4.41 g/t Au over 1.60 metres) and 2.05 g/t Au over 4.30 metres from 65.85 metres (including 4.75 g/t Au over 1.35 metres).
  • Improved core recovery: recovery averaged 98%, compared with approximately 50% or less reported for historical drilling, providing a more complete record of the mineralized zones, including clay-rich fault material that was largely lost in earlier drilling.
  • Potential at depth: vein textures and a fragment of desiccation-cracked mud interpreted to have come from the paleosurface suggest that drilling has tested the shallow levels of an epithermal system, supporting exploration for additional gold mineralization at depth.
  • Further results are pending, with assays awaited for six holes, including TARU2026-03, which twinned the historical hole that returned the highest reported gold grade on the Project.

Aurania completed eight diamond drill holes totalling 780.70 metres during the program. Core recovery averaged 98% compared with approximately 50% or less reported for historical drilling. The improved recovery provides more complete samples of the mineralized zones for geological interpretation and assay comparison. Results from the remaining holes are pending, including TARU2026-03, which was twinned with a historical hole that returned a bonanza grade of 415 g/t Au. The historical results have not been verified by Aurania’s Qualified Person and are not necessarily indicative of results pending for TARU2026-03.

Aurania’s President & CEO, Dr. Keith Barron, commented, “These first results from two twinned holes are very encouraging. TARU2026-05 returned more than 10 g/t gold over four metres of core, and TARU2026-04 returned gold in two separate zones. Although true widths are not yet known, the intersections are consistent with the vein widths seen in historical photographs of the old workings, and they show that gold is distributed across the vein and fault zones. Just as important as the assays are the vein textures in the core, which suggest that we have only just intersected the upper levels of an epithermal system. If that interpretation is correct, veins could continue to depth and be gold mineralized; testing them there will be a priority for follow-up drilling.

Many of the vein intersections are disrupted by post-mineral fault movement, with vein fragments embedded in a clay gouge. Because the host rock is weakly altered basalt, these clay zones may provide strong contrast in electrical geophysical surveys, which could help trace vein structures under cover. That was not apparent before this drill program, as the clay-rich material was largely lost in the historical drilling.

Our first objective was to obtain more complete samples of the mineralized zones and assess how the gold grades compare with historical drilling. The improved core recovery is an important outcome of this program, and we look forward to the results from the remaining six holes. Together, the geological observations and assay results will help us refine our interpretation of the vein system and identify priorities for further exploration.

No arsenic- or antimony-bearing minerals have been observed in the core to date. That is an encouraging early sign, and we have begun preliminary work to evaluate whether material from Thormódsdalur could eventually be shipped directly to an existing processing facility. Multi-element analyses are planned to determine whether any deleterious elements are present.”

Details of Initial Results
Hole TARU2026-04 intersected two mineralized zones. The first was an altered fault gouge with pyrite, accompanied by clasts of fine- banded and massive vein quartz, with individual samples returning up to 6.78 g/t. The second zone comprises a series of banded and colloform veins, commonly broken, returning up to 6.86 g/t Au.

Hole TARU2026-05 intersected a zone of tectonic breccia/cataclastite containing quartz vein clasts, with individual samples returning up to 14.30 g/t Au, transitioning to a zone of intact veining displaying banded, colloform and crustiform textures, with individual samples returning up to 18.35 g/t Au. A second zone, containing a narrow quartz vein, returned 0.71 g/t Au over 1.00 metres from 27.00 metres. Silver grades in both holes were low, as shown in the table below.

HoleFrom (m)To (m)Interval (m)¹Gold (g/t)Silver (g/t)
TARU-0454.5057.002.503.131.00
Including54.5056.101.604.411.00
TARU-04 – second zone65.8570.154.302.050.21
TARU-0520.8525.004.1510.103.72
Including21.5023.902.4015.316.00
TARU-05 – additional zone27.0028.001.000.710.00

¹ Intervals are downhole lengths; true widths are not yet known.
Intervals are length-weighted averages calculated using a lower cut of 0.5 g/t Au, no top cut and a maximum of 1 metre of internal dilution. Silver assays <1 g/t Ag are assigned a value of nil.

Geological Interpretation and Implication for Further Exploration
Gold mineralization occurs in both quartz veins and associated brecciated fault material. This relationship broadens the exploration target beyond the intact veins and will inform the interpretation of the mineralized system and the selection of follow-up drill targets.

Several observations suggest that the drilling has tested the shallow levels of an epithermal system. Colloform and moss-textured quartz, observed throughout the vein intersections, is interpreted to have formed from a primary silica gel near the paleosurface (cf. Dong, Morrison and Jaireth, 1995). Hole TARU2026-05 intersected a short interval of lithified mud with a polygonal cracking pattern, interpreted as desiccation cracks formed at surface; this material may have collapsed into an open hydrothermal vent during the mineralizing event. Silver grades are low and base-metal mineralization is absent, which is also consistent with a high level in the system.

Taken together, these observations support the interpretation that the veins formed a short distance below a former sinter horizon, since removed by glacial erosion, and that the current drilling has tested an upper portion of the system. Epithermal gold deposits preserved immediately below the paleosurface are comparatively uncommon; examples include Fruta del Norte, Ecuador, and McLaughlin, California. Mineralization at those deposits is not necessarily indicative of mineralization at the Project. This interpretation highlights the potential for additional gold mineralization at depth and provides a basis for targeting deeper extensions of the mineralized structures; further drilling is required to establish their continuity, extent and grade. At present, the mineralization is open at depth and along strike to the north and south.

Remaining Results and Next Steps
Assay results are pending for six additional holes and will be reported once received and compiled. Once Aurania has received and reviewed all results, it will integrate the assays with geological logging and historical information to refine its interpretation of the mineralized system and determine priorities for further exploration, which may include deeper drilling and evaluating of geophysical methods to trace the vein structures.

Aurania has initiated preliminary studies to characterize the mineralized material at Thormódsdalur, including multi-element and mineralogical analyses, to assess whether it could be suitable for shipment to a third-party facility for processing without on-site treatment. This work is in the early stages. No mineral resource has been estimated for the Project, and no economic or technical study has been completed, and there is no certainty that this approach will prove viable.

Sampling, Analytical Methods and Quality Assurance/Quality Control
Coring was by wire-line diamond drilling to produce a HQ core of 63.5 mm diameter or HQ3 core of 61.1 mm diameter. Within zones of predicted mineralization HQ3 coring and shorter drill runs were utilized to optimise recovery. HQ core runs were nominally 3 m long, while HQ3 was nominally 1.5 m long but were drilled shorter where required. Samples were sawn in half longitudinally with a diamond blade saw, tagged, and placed in plastic bags for shipment. One half of the core was retained as a reference sample.

Laboratories: The core samples were prepared for analysis at ALS Scandinavia AB Laboratory (“ALS”) in Piteå, Sweden, and the analyses were done at ALS, Loughrea, Galway, Ireland. 

Sample preparation: The rock samples were jaw-crushed to 10 mesh (crushed material passes through a mesh with apertures of 2 millimetres (“mm”)), from which a one-kilogram split was taken. The sub-sample was pulverized to a grain size of 0.075mm.

Analytical procedure: 50 g of rock pulp was analyzed by fire assay with an Atomic Absorption Spectroscopy (“AAS”) finish for gold, and by aqua regia digestion and AAS finish for silver.

Sample Analysis & Quality Assurance / Quality Control (“QAQC”) 
Aurania personnel inserted a certified standard pulp sample, alternating with a certified blank, at approximate 20 sample intervals in all sample batches. Aurania’s analysis of results from its independent QAQC samples showed the batches reported above lie within acceptable limits. In addition, the labs reported that the analyses had passed their internal QAQC tests.

About Thormódsdalur
The Thormódsdalur project is located approximately 20 kilometres east of Reykjavík, Iceland, and is held by Iceland Resources ehf (“IR”), a wholly owned subsidiary of St-Georges Eco-Mining Corp. (“St-Georges”) (CSE: SX). In April 2026, Aurania entered into an option agreement with St-Georges and IR to collaboratively define and execute a phased exploration program to advance the Project toward an initial modern resource definition. The key terms of the option agreement are described in the Company’s news release dated April 28, 2026.

Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Aurania’s VP Exploration, Mr. Jean-Paul Pallier, MSc, who is not independent of the Company. Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, X (formerly Twitter) at https://x.com/AuraniaLtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
[email protected]
 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management’s current expectations and assumptions. The forward-looking information includes: statements regarding the Project, the timing and results of pending assays, the interpretation that drilling has tested the upper levels of an epithermal system, the potential for additional mineralization at depth and along strike, the potential use of geophysical surveys, future metallurgical evaluation, statements regarding the option agreement with St-Georges and IR and the goals, plans and objectives set out thereunder, anticipated exploration programs, timing of activities, the potential to advance the Project, Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the tonnage and grade of mineralization which has the potential for economic extraction and processing, the merits and effectiveness of known process and recovery methods, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations, the commencement of any drill program and estimates of market conditions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to Aurania, including the assumption that there will be no material adverse change in metal prices, all necessary consents, licenses, permits and approvals will be obtained, including various local government licenses, and that market conditions will be favourable. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things: failure to achieve the anticipated results, incorrect assumptions made in the initial evaluation of the Project, failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; the inability to recover and process mineralization using known mining methods; the presence of deleterious mineralization or the inability to process mineralization in an environmentally acceptable manner; commodity prices, supply chain disruptions, restrictions on labour and workplace attendance and local and international travel; a failure to obtain or delays in obtaining the required regulatory licenses, permits, approvals and consents; an inability to access financing as needed; a general economic downturn, a volatile stock price, labour strikes, political unrest, changes in the mining regulatory regime governing Aurania; a failure to comply with environmental regulations; a weakening of market and industry reliance on precious metals and base metals; risks associated with conducting operations in a foreign jurisdiction, including currency fluctuations, foreign regulatory requirements, and cross-border logistical challenges; and those risks set out in the Company’s public documents filed on SEDAR+. Aurania cautions the reader that the above list of risk factors is not exhaustive. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

info

Source: Aurania Resources Ltd.

Release – Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Cocrystal Pharma, Inc.

Research News and Market Data on COCP

November 15, 2026

Download as PDF

  • Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reported
  • Preliminary efficacy results expected near the end of 2026
  • Closed $5 million private placement with OPKO Health
  • Appointed antiviral drug development leader Carol Brosgart, MD, to the Board of Directors

BOTHELL, Wash., Nov. 15, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three and nine months ended September 30, 2026.

“Dosing the last subject in our Phase 1b challenge study brings Cocrystal to a key value inflection point. With the continued support of OPKO Health and a board strengthened by Dr. Brosgart’s antiviral development experience, we are focused on reporting preliminary efficacy data from CDI-988 during late 2026 and positioning the program for its next stage of clinical development,” said James Sapirstein, Chief Executive Officer of Cocrystal.

“With dosing now complete in the Phase 1b challenge study, the preliminary efficacy results will be an important test of what CDI-988 can do. OPKO increased its investment this quarter because norovirus represents both a substantial global need and an equally substantial commercial opportunity, and we believe CDI-988 has the potential to address both,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health and co-founder, director and principal stockholder of Cocrystal.

“The study design lets us evaluate CDI-988 in both prevention and treatment settings, and completing dosing is an important step for the program. With no approved treatments or vaccines for norovirus, we look forward to efficacy data that will guide CDI-988’s path toward later-stage development,” said Sam Lee, Ph.D., President and Chief Scientific Officer of Cocrystal.

The Phase 1b randomized, double-blind, placebo-controlled challenge study (NCT07198139) is being conducted at Emory University School of Medicine. The study enrolled 32 healthy adults, aged 18 to 49, in staged cohorts. Following a stage 1 infectivity cohort, subjects in the prevention and treatment cohorts were inoculated with the norovirus GII.2 (Snow Mountain Virus) strain and received CDI-988 at 1,200 mg twice daily for five days or placebo. The last subject was dosed in September 2026, with no serious adverse events reported. The primary efficacy endpoint is reduction in the incidence of clinical symptoms versus placebo, with secondary endpoints including reduction in viral shedding, disease severity, safety and pharmacokinetics. Preliminary efficacy results are expected in late 2026.

Antiviral Product Pipeline Overview

We leverage our proprietary structure-based drug discovery platform technology to develop next-generation, broad-spectrum antivirals that effectively block viral replication. Unlike other drug discovery approaches, our technology identifies compounds that bind to highly conserved regions of viral drug targets, including proteases and replication enzymes. By specifically targeting these essential viral functions, our drug candidates maintain efficacy as viruses mutate, while simultaneously minimizing off-target interactions that may lead to adverse side effects. This dual advantage represents a significant breakthrough in antiviral drug development. In addition, our innovative methodology fundamentally transforms the conventional drug discovery paradigm by eliminating inefficient, resource-intensive cycles of high-throughput compound screening and prolonged hit-to-lead optimization. The result is faster identification of promising candidates with superior resistance and safety characteristics.

Norovirus Program

Norovirus is a common, highly contagious virus that afflicts people of all ages and causes symptoms of acute gastroenteritis: nausea, vomiting, stomach pain and diarrhea, fatigue, fever and dehydration. There are currently no effective treatments or vaccines for norovirus, and the ability to curtail outbreaks is inadequate.

With 685 million global cases annually and a $60 billion worldwide economic impact, norovirus represents one of healthcare’s most pressing unmet needs. In the U.S., noroviruses are responsible for an estimated 21 million infections annually, including an estimated 109,000 hospitalizations, 465,000 emergency department visits and 900 deaths. The annual burden of norovirus to the U.S. is estimated at $10.6 billion. In the developing world, each year noroviruses are responsible for up to 1.1 million hospitalizations and 218,000 pediatric deaths.

Oral protease inhibitor CDI-988 for the treatment of noroviruses and coronaviruses: Our first oral direct-acting antiviral CDI-988 targets the highly conserved region of the 3CL protease and is designed as a potential therapeutic for noroviruses and coronaviruses. CDI-988 has shown in vitro activity against multiple norovirus strains.

  • In April 2025 we announced that CDI-988 showed superior broad-spectrum antiviral activity against the norovirus GII.17 strain, the most prevalent strain in the U.S. and Europe in 2024-2025.
  • In August 2025 we presented favorable Phase 1 safety and tolerability data from all CDI-988 doses, including a high-dose 1,200 mg cohort, at the 2025 Military Health System Research Symposium (MHSRS).
  • In September 2025 we discussed CDI-988’s scientific foundation and clinical progress in an oral presentation at the 9th International Calicivirus Conference, the leading calicivirus scientific meeting.
  • In September 2025 we received a Study May Proceed Letter from the FDA to conduct a Phase 1b challenge study in the U.S. evaluating CDI-988 as a norovirus preventive and treatment.
  • In March 2026 we enrolled the first subjects in our Phase 1b challenge study, which is being conducted at Emory University School of Medicine.
  • In April 2026 we announced full enrollment in the first cohort of the Phase 1b study, which is evaluating the infectivity rate of the GII.2 challenge inoculum, at the International Conference on Antiviral Research 2026 (ICAR 2026).
  • In April 2026 we were granted FDA Fast Track designation for CDI-988, enabling the potential for an accelerated development pathway.
  • In September 2026 we dosed the last subject in the Phase 1b challenge study, with no serious adverse events reported to date.
  • We expect to report preliminary efficacy results from the Phase 1b study near the end of 2026

Influenza Programs

Influenza is a major global health threat that may become more challenging to treat due to the emergence of highly pathogenic avian influenza viruses and resistance to approved influenza antivirals. Currently approved antiviral treatments for influenza are effective but are burdened with significant viral resistance.

Each year approximately 1 billion cases of seasonal influenza, 3-5 million severe illnesses and up to 650,000 deaths are reported worldwide. About 8% of the U.S. population gets sick from flu each season. In addition to the health risk, influenza is responsible for an estimated $10.4 billion in direct medical costs in the U.S. each year.

CC-42344 is our novel PB2 inhibitor that showed excellent in vitro activity against pandemic and seasonal influenza A strains, as well as against strains that are resistant to Tamiflu® and Xofluza®.

Oral CC-42344 as a treatment for pandemic and seasonal influenza A

  • In December 2022 we reported favorable Phase 1 safety and tolerability results.
  • In December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, and viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory Agency.
  • In May 2025 we reported that CC-42344 was shown to be active against the highly pathogenic 2024 Texas H5N1 avian influenza strain.
  • In November 2025 an initial Phase 2a study was completed, with CC-42344 showing a favorable safety and tolerability profile with no serious adverse events and no drug-related discontinuations by study participants. Efficacy analyses were not reported due to issues with trial conduct.
  • We plan to continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A with an additional Phase 2a study.

Inhaled CC-42344 as prophylaxis and treatment for pandemic and seasonal influenza A

  • Our preclinical testing showed superior pulmonary pharmacology with CC-42344, including high exposure to drug and a long half-life.
  • We have developed a dry powder inhalation formulation of CC-42344 and have completed toxicology studies.

Influenza A/B program

  • In October 2025 we were awarded an approximately $500,000 Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases to support the development of a novel, broad-spectrum lead candidate targeting the influenza A/B polymerase complex.

Recent Corporate Developments

  • On July 31, 2026, the Company entered into a Securities Purchase Agreement with longtime investor OPKO Health, Inc. (Nasdaq: OPK), under which the Company sold 5,474,053 shares of common stock at $0.9134 per share, the Nasdaq Consolidated Bid Price on the trading day of closing, for gross proceeds of $5.0 million. The Company intends to use the net proceeds for the advancement of its preclinical and clinical drug candidate programs, and for general corporate purposes and working capital.
  • In August 2026 the Company appointed Carol Brosgart, MD, to its Board of Directors, effective August 12, 2026. Dr. Brosgart spent more than a decade at Gilead Sciences, where she played a critical role in the development and regulatory approval of the antiviral therapies Viread® and Hepsera®. She currently serves as Clinical Professor of Medicine, Biostatistics and Epidemiology at the University of California, San Francisco (UCSF) School of Medicine.

Third Quarter 2026 Financial Results

Three-Month Results
Revenue and grant income for the three months ended September 30, 2026 was $105,000 compared to no revenue for the third quarter of 2025, representing payments from the NIH SBIR award for an influenza A/B inhibitor program.

Total research and development expenses for the three months ended September 30, 2026, and 2025 were $1,978,000 and $954,000, respectively. The increase of $1,024,000 was primarily due to costs associated with the Phase 1b norovirus challenge study of our norovirus candidate CDI-988 in 2026. We expect to report preliminary efficacy results near the end of 2026.

General and administrative expenses for the three months ended September 30, 2026, and 2025 were $1,616,000 and $1,135,000, respectively. The increase of $481,000 was primarily due to an increase in salaries and wages of $160,000 to support the clinical trials, investor and public relation expenses of $316,000 and legal expenses of $145,000, partially offset with a decrease of $140,000 in other general and administrative expenses.

As a result of the above factors, net loss for the three months ended September 30, 2026 was $3,444,000, compared with a net loss of $2,049,000 for the three ended September 30, 2025, respectively, primarily as a result of operations described above.

Nine-Month Results
Revenue and grant income for the nine months ended September 30, 2026 was $435,000 compared to no revenue for the nine months ended September 30, 2025, representing payments from the NIH SBIR award for an influenza A/B inhibitor program.

Total research and development expenses for the nine months ended September 30, 2026, and 2025 were $5,491,000 and $3,436,000, respectively. The increase of $2,055,000 was primarily due to costs associated with the Phase 1b norovirus challenge study of our norovirus candidate CDI-988 in 2026.

General and administrative expenses for the nine months ended September 30, 2026, and 2025 were $3,973,000 and $3,102,000, respectively. The increase of $871,000 was primarily due to increases in salaries and wages of $207,000 to support the clinical trials, investor and public relation expenses of $431,000, legal expenses of $173,000 and $60,000 in other general and administrative expenses.

As a result of the above factors, net loss for the nine months ended September 30, 2026 was $8,907,000, compared with a net loss of $6,405,000 for the nine months ended September 30, 2025, respectively, primarily as a result of operations described above.

Cocrystal reported unrestricted cash as of September 30, 2026, of $4,873,000 reflecting $5.0 million in gross proceeds from the OPKO Health private placement. Net cash used in operating activities was $7,152,000 for the nine months ended September 30, 2026. The Company had working capital of $2,311,000 as of September 30, 2026.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. The Company’s lead program, CDI-988, is currently in a Phase 1b clinical trial for norovirus, with preliminary efficacy results expected near the end of 2026 or early 2027. Cocrystal employs unique structure-based technologies to create differentiated antiviral drug candidates. For more information, visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s progress, anticipated timeline and expectations for preliminary efficacy results from its norovirus Phase 1b clinical trial, and the continued development of its influenza, coronaviruses, and hepatitis C, and other antiviral programs and the results thereof. Words such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” and “expect,” as they relate to the Company, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from inflation, affordability, the possibility of a recession, increases or other developments with respect to interest rates, uncertainty surrounding the impacts arising from imposed and threatened tariffs and developments with respect thereto, and wars and geopolitical conflicts including those in Ukraine and with Iran on our Company, our collaboration partners, and on the U.S. and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials and test subjects, including animals as well as similar problems with our vendors our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, risks arising from research into a related virus that was not done in animals and was necessarily early stage, the results of the Phase 1b clinical trial and future preclinical and clinical trials including the potential for adverse findings, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes and potential litigation challenging initiatives and actions taken by the Trump Administration which could, among other things, result in delays in regulatory approvals or limit access to federal funding for our programs, development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government, potential mutations in a virus we are targeting which may result in variants that are resistant to a product candidate we develop, and our liquidity and ability to raise necessary capital on acceptable terms or at all. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
Nic Johnson
Russo Partners
[email protected]
(303) 482-6405

Media Contact:
David Schull
Russo Partners
[email protected]
(858) 717-2310

View full release here.